’†‘”_‹Æ‰ÈŠw‰@ ƒnƒ‹ƒrƒ“bˆãŒ¤‹†Š’†‘”_‹Æ‰ÈŠw‰@ ƒnƒ‹ƒrƒ“bˆãŒ¤‹†Š

Œ¤‹†¬‰Ê

˜_•¶”­•\

2023

  1. Chiba S, Kong H, Neumann G, Kawaoka Y. Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes. mBio, in press.
  2. Muramoto Y, Takahashi S, Halfmann PJ, Gotoh S, Noda T, Kawaoka Y. Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures. Lancet Microbe, in press.
  3. Yamayoshi S, Ito M, Iwatsuki-Horimoto K, Yasuhara A, Okuda M, Hamabata T, Murakami J, Duong C, Yamamoto T, Kuroda Y, Maeda K, Kawaoka Y. Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan, 2023. One Health 17:100588. doi: 10.1016/j.onehlt.2023.100588. 2023. (DEC 2023)
  4. Halfmann PJ, Uraki R, Kuroda M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Kawaoka Y. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters. EBioMedicine 93:104677, 2023. doi: 10.1016/j.ebiom.2023.104677. 2023. (JUL 2023)
  5. Kiso M, Furusawa Y, Uraki R, Imai M, Yamayoshi S, Kawaoka Y. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nat Commun 14(1): 3952, 2023. doi: 10.1038/s41467-023-39704-x. 2023. (JUL 2023)
  6. Ishizaka A, Koga M, Mizutani T, Uraki R, Yamayoshi S, Iwatsuki-Horimoto K, Yamamoto S, Imai M, Tsutsumi T, Suzuki Y, Kawaoka Y, Yotsuyanagi H. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination. Virol J 20(1): 146, 2023. doi: 10.1186/s12985-023-02113-z. 2023. (JUL 2023)
  7. Kiso M, Yamayoshi S, Iida S, Furusawa Y, Hirata Y, Uraki R, Imai M, Suzuki T, Kawaoka Y. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. Nat Commun 14(1): 4231. doi: 10.1038/s41467-023-40018-1. 2023. (JUL 2023)
  8. Kiso M, Yamayoshi S, Kawaoka Y. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors. J Antimicrob Chemother 78(7): 1649-1657, 2023. doi: 10.1093/jac/dkad145. 2023. (JUL 2023)
  9. Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y. Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination. iScience 26(7): 107208, 2023. doi: 10.1016/j.isci.2023.107208. 2023. (JUN 2023)
  10. Tamura D, Kawaoka Y. Omicron proliferation in the nasal cavity may explain its high infectivity. J Infect 86(6): 584-587, 2023. doi: 10.1016/j.jinf.2023.03.006. 2023. (JUN 2023)
  11. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Theiler J, Yotsuyanagi H, Suzuki Y, Korber B, Kawaoka Y. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate. Lancet Reg Health West Pac 34: 100777, 2023. doi: 10.1016/j.lanwpc.2023.100777. 2023. (MAY 2023)
  12. Furusawa Y, Kiso M, Iida S, Uraki R, Hirata Y, Imai M, Suzuki T, Yamayoshi S, Kawaoka Y. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. EBioMedicine 91:104561, 2023. doi: 10.1016/j.ebiom.2023.104561. 2023. (MAY 2023)
  13. Sakai-Tagawa Y, Yamayoshi S, Halfmann PJ, Wilson N, Bobholz M, Vuyk WC, Wei W, Ries H, O'Connor DH, Friedrich TC, Sordillo EM, van Bakel H, Simon V, Kawaoka Y. Sensitivity of rapid antigen tests for Omicron subvariants of SARS-CoV-2. J Med Virol 95(5): e28788, 2023. doi: 10.1002/jmv.28788. 2023. (MAY 2023)
  14. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1. Lancet Infect Dis 23(5): 525-526, 2023. doi: 10.1016/S1473-3099(23)00132-9. 2023. (MAY 2023)
  15. Guan L, Zhong G, Fan S, Plisch EM, Presler R, Gu C, Babujee L, Pattinson D, Le Khanh Nguyen H, Hoang VMP, Le MQ, van Bakel H, Neumann G, Kawaoka Y. Highly Pathogenic H5 Influenza Viruses Isolated between 2016 and 2017 in Vietnamese Live Bird Markets. Viruses. 15(5):1093, 2023. doi: 10.3390/v15051093. 2023. (APR 2023)
  16. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann P, Pekosz A, Kawaoka Y. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Inf Dis 23(4): 402-403, 2023. doi: 10.1016/S1473-3099(23)00070-1. 2023. (APR 2023)
  17. Changrob S, Halfmann PJ, Liu H, Torres JL, McGrath JJC, Ozorowski G, Li L, Wilbanks GD, Kuroda M, Maemura T, Huang M, Zheng NY, Turner HL, Erickson SA, Fu Y, Yasuhara A, Singh G, Monahan B, Mauldin J, Srivastava K, Simon V, Krammer F, Sather DN, Ward AB, Wilson IA, Kawaoka Y, Wilson PC. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct Omicron subvariants. J Clin Invest 133(8): e166844, 2023. doi: 10.1172/JCI166844. 2023. (APR 2023)
  18. Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Nat Commun 14(1): 1620. doi: 10.1038/s41467-023-37059-x. 2023. (MAR 2023)
  19. Furusawa Y, Yamayoshi S, Kawaoka Y. The accuracy of reverse genetics systems for SARS-CoV-2: Circular polymerase extension reaction versus bacterial artificial chromosome. Influenza Other Respir Viruses 17(3): e13109. doi: 10.1111/irv.13109. 2023. (MAR 2023)
  20. Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nat Commun 14(1): 1076. doi: 10.1038/s41467-023-36729-0. 2023. (FEB 2023)
  21. Soga T, Duong C, Pattinson D, Sakai-Tagawa Y, Tokita A, Izumida N, Nishino T, Hagiwara H, Wada N, Miyamoto Y, Kuroki H, Hayashi Y, Seki M, Kasuya N, Koga M, Adachi E, Iwatsuki-Horimoto K, Yotsuyanagi H, Yamayoshi S, Kawaoka Y. Characterization of influenza A(H1N1)pdm09 viruses isolated in the 2018-2019 and 2019-2020 influenza seasons in Japan. Viruses 15(2): 535. doi: 10.3390/v15020535. 2023. (FEB 2023)
  22. Neumann G, Kawaoka Y. The COVID-19 pandemic-a potential role for antivirals in mitigating pandemics. Viruses 15(2): 303. doi: 10.3390/v15020303. 2023. (JAN 2023)
  23. Iwatsuki-Horimoto K, Ueki H, Ito M, Nagasawa S, Hirata Y, Hashizume K, Ushiwata K, Iwase H, Makino Y, Ushiku T, Akitomi S, Imai M, Saitoh H, Kawaoka Y. SARS-CoV-2 transmission from virus-infected dead hamsters. mSphere 8(1): e0041122. doi: 10.1128/msphere.00411-22. 2023. (FEB 2023)
  24. Koga M, Iwatsuki-Horimoto K, Kikuchi T, Yamayoshi S, Kawaoka Y, Yotsuyanagi H. Previous Omicron infection may be protective against reinfection with Omicron variant BA.5 for at least five months. Clin Microbiol Infect 29(1):120-121, 2023. doi: 10.1016/j.cmi.2022.09.009. (JAN 2023)
  25. Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann P, Kawaoka Y. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N Engl J Med 388(1):89-91, 2023. doi: 10.1056/NEJMc2214302. (JAN 2023)
  26. Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Saito M, Koga M, Tsutsumi T, Yamamoto S, Otani A, Kiso M, Sakai-Tagawa Y, Ueki H, Yotsuyanagi H, Imai M, Kawaoka Y. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis 23(1):30-32, 2023. doi: 10.1016/S1473-3099(22)00816-7. (JAN 2023)
  27. Chiba S, Hatta M, Pattinson D, Yasuhara A, Neumann G, Kawaoka Y. Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses. Vaccine 41(2):590-597, 2023. doi: 10.1016/j.vaccine.2022.12.005. (JAN 2023)
  28. Takashita E, Watanabe S, Hasegawa H, Kawaoka Y. Are twindemics occurring? Influenza Other Respir Viruses 17(1): e13090. doi: 10.1111/irv.13090. (JAN 2023)
  29. Neumann G, Kawaoka Y. Which virus will cause the next pandemic? Viruses 15(1): 199, 2023. doi: 10.3390/v15010199. (JAN 2023)

2022

  1. Boon ACM, Darling TL, Halfmann PJ, Franks J, Webby RJ, Barouch DH, Port JR, Munster VJ, Diamond MS, Kawaoka Y. Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters. PLoS Pathog 18(12): e1010970, 2022. doi: 10.1371/journal.ppat.1010970. (DEC 2022)
  2. Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612(7940):540-545, 2022. doi: 10.1038/s41586-022-05482-7. (DEC 2022)
  3. Takashita E, Yamayoshi S, Halfmann P, Wilson N, Ries H, Richardson A, Bobholz M, Vuyk W, Maddox R, Baker DA, Friedrich TC, O'Connor DH, Uraki R, Ito M, Sakai-Tagawa Y, Adachi E, Saito M, Koga M, Tsutsumi T, Iwatsuki-Horimoto K, Kiso M, Yotsuyanagi H, Watanabe S, Hasegawa H, Imai M, Kawaoka Y. In vitro efficacy of antiviral agents against Omicron subvariant BA.4.6. N Engl J Med 387(22):2094-2097, 2022. doi: 10.1056/NEJMc2211845. (DEC 2022)
  4. Nagai H, Saito M, Adachi E, Sakai-Tagawa Y, Yomayoshi S, Kiso M, Kawamata T, Koga M, Kawaoka Y, Tsutsumi T, Yotsuyanagi H. Casirivimab/imdevimab for active COVID-19 pneumonia persisted for nine months in a patient with follicular lymphoma during anti-CD20 therapy. Jpn J Infect Dis 75(6): 608-611, 2023. doi: 10.7883/yoken.JJID.2022.092. (NOV 2022)
  5. Yamayoshi S, Iwatsuki-Horimoto K, Okuda M, Ujie M, Yasuhara A, Murakami J, Duong C, Hamabata T, Ito M, Chiba S, Kobayashi R, Takahashi S, Mitamura K, Hagihara M, Shibata A, Uwamino Y, Hasegawa N, Ebina T, Izumi A, Kato H, Nakajima H, Sugaya N, Seki Y, Iqbal A, Kamimaki I, Yamazaki M, Kawaoka Y, Furuse Y. Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020–March 2022, Japan. Emerg Infect Dis 28(11): 2198-2205, 2022. (NOV 2022)
  6. Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Okuda M, Kawaoka Y. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nat Commun 13(1): 6602, 2022. (NOV 2022)
  7. Okuda M, Sakai-Tagawa Y, Koga M, Koibuchi T, Kikuchi T, Adachi E, Lim LA, Yamamoto S, Yotsuyanagi H, Negishi K, Jubishi D, Yamayoshi S, Kawaoka Y. Immunological correlates of prevention of the onset of seasonal H3N2 influenza. J Infect Dis 226(10): 1800-1808, 2022. (NOV 2022)
  8. Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, Ito M, Uraki R, Halfmann P, Watanabe S, Takeda M, Hasegawa H, Imai M, Kawaoka Y. Efficacy of antiviral agents against the Omicron subvariant BA.2.75. N Engl J Med 387(13):1236-1238, 2022. (SEP 2022)
  9. Uraki R, Kiso M, Imai M, Yamayoshi S, Ito M, Fujisaki S, Takashita E, Ujie M, Furusawa Y, Yasuhara A, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Watanabe S, Hasegawa H, Kawaoka Y. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nat Microbiol 7(8): 1252-1258, 2022. (AUG 2022)
  10. Ueki H, Ujie M, Komori Y, Kato T, Imai M, Kawaoka Y. Effectiveness of HEPA filters at removing infectious SARS-CoV-2 from the air. mSphere 7(4): e0008622, 2022. (AUG 2022)
  11. Meng F, Yang H, Qu Z, Chen Y, Zhang Y, Zhang Y, Liu L, Zeng X, Li C, Kawaoka Y, Chen H. A Eurasian avian-like H1N1 swine influenza reassortant virus became pathogenic and highly transmissible due to mutations in its PA gene. Proc Natl Acad Sci U S A 119(34): e2203919119, 2022. (AUG 2022)
  12. Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med 387(5):468-470, 2022. (AUG 2022)
  13. Halfmann PJ, Kuroda M, Armbrust T, Theiler J, Balaram A, Moreno GK, Accola MA, Iwatsuki-Horimoto K, Valdez R, Stoneman E, Braun K, Yamayoshi S, Somsen E, Baczenas JJ, Mitamura K, Hagihara M, Adachi E, Koga M, McLaughlin M, Rehrauer W, Imai M, Yamamoto S, Tsutsumi T, Saito M, Friedrich TC, O'Connor SL, O'Connor DH, Gordon A, Korber B, Kawaoka Y. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. Sci Transl Med. eabm4908, 2022. (AUG 2022)
  14. Patania OM, Chiba S, Halfmann PJ, Hatta M, Maemura T, Bernard KA, Kawaoka Y, Crawford LK. Pulmonary lesions induced by SARS-CoV-2 infection in domestic cats. Vet Pathol 59(4):696-706, 2022. (JUL 2022)
  15. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team, Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Nature 607(7917): 119-127, 2022. (JUL 2022)
  16. Fisher T, Gluck A, Narayanan K, Kuroda M, Nachshon A, Hsu JC, Halfmann PJ, Yahalom-Ronen Y, Tamir H, Finkel Y, Schwartz M, Weiss S, Tseng CK, Israely T, Paran N, Kawaoka Y, Makino S, Stern-Ginossar N. Parsing the role of NSP1 in SARS-CoV-2 infection. Cell Rep 39(11):110954, 2022. (JUN 2022)
  17. Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T, Inoue M, Okuda M, Yasuhara A, Murakami J, Duong C, Iwatsuki-Horimoto K, Yamayoshi S, Kawaoka Y. Anti-SARS CoV-2 IgG in COVID-19 patients with hematological diseases: a single-center, retrospective study in Japan. Intern Med 61(11) :1681-1686, 2022. doi: 10.2169/internalmedicine.9209-21. (JUN 2022)
  18. Darling TL, Ying B, Whitener B, VanBlargan LA, Bricker TL, Liang CY, Joshi A, Bamunuarachchi G, Seehra K, Schmitz AJ, Halfmann PJ, Kawaoka Y, Elbashir SM, Edwards DK, Thackray LB, Diamond MS, Boon ACM. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. Med (N Y) 3(5): 309-324.e6, 2022. (MAY 2022)
  19. Halfmann PJ, Kuroda M, Maemura T, Chiba S, Armbrust T, Wright R, Balaram A, Florek KR, Bateman AC, Kawaoka Y. Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters. Cell Rep 39(3): 110688, 2022. (APR 2022)
  20. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N Engl J Med 386(15): 1475-1477, 2022. (APR 2022)
  21. Ueki H, Ito M, Furusawa Y, Yamayoshi S, Inoue SI, Kawaoka Y. A 265-nanometer high-power deep-UV light-emitting diode rapidly inactivates SARS-CoV-2 aerosols. mSphere 7: e0094121, 2022. (APR 2022)
  22. Murakami J, Shibata A, Neumann G, Imai M, Watanabe T, Kawaoka Y. Characterization of H9N2 Avian influenza viruses isolated from poultry products in a mouse model. Viruses 14: 728. 2022. (MAR 2022)
  23. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. N Engl J Med 386: 995-998, 2022. (MAR 2022)
  24. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, Pinto D, VanBlargan LA, De Marco A, di Iulio J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse KR, Dillen JR, Powell AE, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko NM, Logue J, Iqbal NT, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippà PE, Franzetti-Pellanda A, Garzoni C, Halfmann PJ, Kawaoka Y, Hebner C, Purcell LA, Piccoli L, Pizzuto MS, Walls AC, Diamond MS, Telenti A, Virgin HW, Lanzavecchia A, Snell G, Veesler D, Corti D. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602(7898): 664-670, 2022. (FEB 2022)
  25. Takamatsu Y, Imai M, Maeda K, Nakajima N, Higashi-Kuwata N, Iwatsuki-Horimoto K, Ito M, Kiso M, Maemura T, Takeda Y, Omata K, Suzuki T, Kawaoka Y, Mitsuya H. Highly neutralizing COVID-19 convalescent plasmas potently block SARS-CoV-2 replication and pneumonia in syrian hamsters. J Virol 96: e01551-21, 2022. (FEB 2022)
  26. Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M; Genotype to Phenotype Japan (G2P-Japan) Consortium, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602: 300-306, 2022. (FEB 2022)
  27. Halfmann PJ, Kuroda M, Armbrust T, Accola M, Valdez R, Kowalski-Dobson T, Rehrauer W, Gordon A, Kawaoka Y. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. Cell Rep 38: 110394, 2022. (FEB 2022)
  28. Cameroni E, Bowen J, Rosen L, Saliba C, Zepeda S, Culap K, Pinto D, VanBlargan L, Marco A, Iulio J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse K, Dillen J, Powell A, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko N, Logue J, Iqbal N, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippà P, Franzetti-Pellanda A, Garzoni C, Halfmann P, Kawaoka Y, Hebner C, Purcell L, Piccoli L, Pizzuto M, Walls A, Diamond M, Telenti A, Virgin H, Lanzavecchia A, Snell G, Veesler D, Corti D. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602: 664-670, 2022. (FEB 2022)
  29. Halfmann P, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer S, Darling T, Joshi A, Loeber S, Singh G, Foster S, Ying B, Case J, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio J, Hernandez-Ortiz J, Henry A, Ciouderis K, Florek K, Patel M, Odle A, Wong LY, Bateman A, Wang Z, Edara VV, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche A, Sordillo E, Chang L, Bakel H, Simon V, PSP study group, Douek D, Sullivan N, Thackray L, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby R, Seder R, Suthar M, Garcia-Sastre A, Schotsaert M, Suzuki T, Boon A, Diamond M, KawaokaY. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603: 687-692, 2022. (JAN 2022)
  30. VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 19: 1-6, 2022. (JAN 2022)
  31. Ohta M, Bannai H, Kambayashi Y, Tamura N, Tsujimura K, Yamayoshi S, Kawaoka Y, Nemoto M. Growth properties and immunogenicity of a virus generated by reverse genetics for an inactivated equine influenza vaccine. Equine Vet J 54: 139-144, 2022. (JAN 2022)

2021

  1. Kong X, Guan L, Shi J, Kong H, Zhang Y, Zeng X, Tian G, Liu L, Li C, Kawaoka Y, Deng G, Chen H. A single-amino-acid mutation at position 225 in hemagglutinin attenuates H5N6 influenza virus in mice. Emerg Microbes Infect 10: 2052-2061, 2021. (DEC 2021)
  2. Kong H, Fan S, Takada K, Imai M, Neumann G, Kawaoka Y. H3N2 influenza viruses with 12- or 16-amino acid deletions in the receptor-binding region of their hemagglutinin protein. mBio 12: e0151221, 2021. (DEC 2021)
  3. Asaka MN, Utsumi D, Kamada H, Nagata S, Nakachi Y, Yamaguchi T, Kawaoka Y, Kuba K, Yasutomi Y. Highly susceptible SARS-CoV-2 model in CAG promoter-driven hACE2 transgenic mice. JCI Insight 6(19): e152529, 2021. (OCT 2021)
  4. Maemura T, Kuroda M, Armbrust T, Yamayoshi S, Halfmann PJ, Kawaoka Y. Antibody-dependent enhancement of SARS-CoV-2 infection is mediated by the IgG receptors FcγRIIA and FcγRIIIA but does not contribute to aberrant cytokine production by macrophages. mBio 12, 2021. (OCT 2021)
  5. Sakai-Tagawa Y, Yamayoshi S, Halfmann P, Kawaoka Y. Comparative sensitivity of rapid antigen tests for the Delta variant (B.1.617.2) of SARS-CoV-2. Viruses 13: 2183, 2021. (OCT 2021)
  6. Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Eisfeld AJ, Baczenas JJ, Baker DA, O'Connor SL, O'Connor DH, Fukushi S, Fujimoto T, Kuroda Y, Gordon A, Maeda K, Ohmagari N, Sugaya N, Yotsuyanagi H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc Natl Acad Sci U S A 118(27): e2106535118, 2021. (JUL 2021)
  7. Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, Zheng NY, Huang M, Shaw DG, Cobb MS, Erickson SA, Guthmiller JJ, Stovicek O, Wang J, Winkler ES, Madariaga ML, Shanmugarajah K, Jansen MO, Amanat F, Stewart I, Utset HA, Huang J, Nelson CA, Dai YN, Hall PD, Jedrzejczak RP, Joachimiak A, Krammer F, Diamond MS, Fremont DH, Kawaoka Y, Wilson PC. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54(6): 1290-1303.e7, 2021. (JUN 2021)
  8. Saito M, Itoh Y, Yasui F, Munakata T, Yamane D, Ozawa M, Ito R, Katoh T, Ishigaki H, Nakayama M, Shichinohe S, Yamaji K, Yamamoto N, Ikejiri A, Honda T, Sanada T, Sakoda Y, Kida H, Le TQM, Kawaoka Y, Ogasawara K, Tsukiyama-Kohara K, Suga H, Kohara M. Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models. Nat Commun 12(1): 2654, 2021. (MAY 2021)
  9. Uwamino Y, Nagata M, Aoki W, Nakagawa T, Inose R, Yokota H, Furusawa Y, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kawaoka Y, Hasegawa N, Murata M; Keio Donner Project Members. Accuracy of rapid antigen detection test for nasopharyngeal swab specimens and saliva samples in comparison with RT-PCR and viral culture for SARS-CoV-2 detection. J Infect Chemother S1341-321X(21)00117-3, 2021. (APR 2021)
  10. Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, Kumazaki M, Usuku S, Tanaka N, Okubo I, Morita H, Nagata S, Watanabe S, Hasegawa H, Kawaoka Y. Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic. Influenza Other Respir Viruses 15(4): 488-494, 2021. (JUL 2021)
  11. Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, Akasaka O, Koga M, Adachi E, Saito M, Nakachi I, Ogura T, Baba R, Ito M, Kiso M, Yasuhara A, Yamada S, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Yamayoshi S, Yotsuyanagi H, Kawaoka Y, Khurana S. Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution. Sci Adv 7(10): eabf2467, 2021. (MAR 2021)
  12. Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I, Koga M, Mitamura K, Yagi K, Maeda K, Kato H, Nojima M, Pattinson D, Ogura T, Baba R, Fujita K, Nagai H, Yamamoto S, Saito M, Adachi E, Ochi J, Hattori SI, Suzuki T, Miyazato Y, Chiba S, Okuda M, Murakami J, Hamabata T, Iwatsuki-Horimoto K, Nakajima H, Mitsuya H, Omagari N, Sugaya N, Yotsuyanagi H, Kawaoka Y. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine 32: 100734, 2021. (FEB 2021)
  13. Kong H, Burke DF, da Silva Lopes TJ, Takada K, Imai M, Zhong G, Hatta M, Fan S, Chiba S, Smith D, Neumann G, Kawaoka Y. Plasticity of the influenza virus H5 HA protein. mBio 12(1): e03324-20, 2021. (FEB 2021)
  14. Chiba S, Halfmann PJ, Hatta M, Maemura T, Fan S, Armbrust T, Swartley OM, Crawford LK, Kawaoka Y. Protective immunity and persistent lung sequelae in domestic cats after SARS-CoV-2 Infection. Emerg Infect Dis 27(2): 660-663, 2021. (FEB 2021)

2020

  1. Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, Maeda K, Adachi E, Saito M, Nagai H, Ikeuchi K, Ogura T, Baba R, Fujita K, Fukui T, Ito F, Hattori SI, Yamamoto K, Nakamoto T, Furusawa Y, Yasuhara A, Ujie M, Yamada S, Ito M, Mitsuya H, Omagari N, Yotsuyanagi H, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Comparison of rapid antigen tests for COVID-19. Viruses 12(12): 1420, 2020. (DEC 2020)
  2. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH 3rd, Leist SR, Schëfer A, Nakajima N, Takahashi K, Lee RE, Mascenik TM, Graham R, Edwards CE, Tse LV, Okuda K, Markmann AJ, Bartelt L, de Silva A, Margolis DM, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370(6523):1464-1468, 2020. (DEC 2020)
  3. Ueki H, Furusawa Y, Iwatsuki-Horimoto K, Imai M, Kabata H, Nishimura H, Kawaoka Y. Effectiveness of face masks in preventing airborne transmission of SARS-CoV-2. mSphere 5:e00637-20, 2020. (OCT 2020)
  4. Fukuyama S, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Gregg RW, Katsura H, Tomita Y, Maemura T, da Silva Lopes TJ, Watanabe T, Shoemaker JE, Hasegawa H, Yamayoshi S, Kawaoka Y. Pathogenesis of influenza A(H7N9) virus in aged nonhuman primates. J Infect Dis 222(7): 1155-1164, 2020. (OCT 2020)
  5. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M, Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H, Yasuhara A, Sakai-Tagawa Y, Lopes TJS, Kiso M, Yamayoshi S, Kinoshita N, Ohmagari N, Hattori SI, Takeda M, Mitsuya H, Krammer F, Suzuki T, Kawaoka Y. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci USA 117(28): 16587-16595, 2020. (JUL 2020)
  6. Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses 12(6): 629, 2020. (JUN 2020)
  7. Kiso M, Yamayoshi S, Kawaoka Y. Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice. Commun Biol 3(1): 219, 2020. (MAY 2020)
  8. Feng H, Nakatsu S, Lopes TJDS, Imai M, Yamayoshi S, Yamashita M, Watanabe T, Kawaoka Y. Identification of novel adjuvants for ebola virus-like particle vaccine. Vaccines (Basel) 8: E215, 2020. (MAY 2020)
  9. Kato-Miyashita, S, Sakai-Tagawa Y, Yamashita M, Iwatsuki-Horimoto K, Ito M, Tokita A, Hagiwara H, Izumida N, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Yotsuyanagi H, Kawaoka Y, Imai M. Antigenic variants of influenza B viruses isolated in Japan during the 2017â€E018 and 2018â€E019 influenza seasons. Influenza Other Respi Viruses 14: 311-319, 2020. (MAY 2020)
  10. Kiso M, Yamayoshi S, Murakami J, Kawaoka Y. Baloxavir marboxil treatment of nude mice infected with influenza A virus. J Infect Dis 221: 1699-1702, 2020. (APR 2020)
  11. Ueki H, Wang IH, Zhao D, Gunzer M, Kawaoka Y. Multicolor two-photon imaging of in vivo cellular pathophysiology upon influenza virus infection using the two-photon IMPRESS. Nat Protoc 15: 1041-1065, 2020. (MAR 2020)
  12. Wu L, Mitake H, Kiso M, Ito M, Iwatsuki-Horimoto K, Yamayoshi S, Lopes TJS, Feng H, Sumiyoshi R, Shibata A, Osaka H, Imai M, Watanabe T, Kawaoka Y. Characterization of H7N9 avian influenza viruses isolated from duck meat products. Transboundary and Emerging Diseases 67: 792-798, 2020. (MAR 2020)
  13. Maemura T, Fukuyama S, Kawaoka Y. High levels of miR-483-3p are present in serum exosomes upon infection of mice with highly pathogenic avian influenza virus. Front Microbiol 11: 144, 2020. (FEB 2020)
  14. Zhong G, Fan S, Hatta M, Nakatsu S, Walters KB, Lopes TJS, Wang JI, Ozawa M, Karasin A, Li Y, Tong S, Donis RO, Neumann G, Kawaoka Y. Mutations in the NA-like protein of bat influenza H18N11 virus enhance virus replication in mammalian cells, mice, and ferrets. J Virol 94: e01416-19, 2020. (FEB 2020)
  15. Mitake H, Yasuhara A, Lopes TJS, Tagawa-Sakai Y, Shimizu K, Ozawa H, Kawakami C, Morikawa S, Sugaya N, Watanabe T, Kawaoka Y. Comparison of the Pathogenicity in Mice of A(H1N1)pdm09 Viruses Isolated between 2009 and 2015 in Japan. Viruses 12(2). pii: E155, 2020. (JAN 2020)
  16. Imai M, Yamashita M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kiso M, Murakami J, Yasuhara A, Takada K, Ito M, Nakajima N, Takahashi K, Lopes TJS, Tokita A, Hagiwara H, Izumida N, Kuroki H, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Hasegawa H, Kawaoka Y. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nature Microbiology 5: 27-33, 2020. (JAN 2020)

2019

  1. Kuwahara T, Yamayoshi S, Noda T, Kawaoka Y. G protein pathway suppressor 1 promotes influenza virus polymerase activity by activating the NF-κB signaling pathway. Mbio 10(6): e02867-19, 2019. (DEC2019)
  2. Kiso M, Yamayoshi S, Furusawa Y, Kawaoka Y. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil. Viruses 11(11): 1066, 2019. (NOV 2019)
  3. Arikata M, Itoh Y, Shichinohe S, Nakayama M, Ishigaki H, Kinoshita T, Le MQ, Kawaoka Y, Ogasawara K, Shimizu T. Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antiviral Res 171: 104591, 2019. (NOV 2019)
  4. Matsuzawa Y, Iwatsuki-Horimoto K, Nishimoto Y, Abe Y, Fukuyama S, Hamabata T, Okuda M, Go Y, Watanabe T, Imai M, Arai Y, Fouchier RAM, Yamayoshi S, Kawaoka Y. Antigenic change in human influenza A(H2N2) viruses detected by using human plasma from aged and younger adult individuals. Viruses 11(11): 978, 2019. (OCT 2019)
  5. Feldmann F, Kobasa D, Embury-Hyatt C, Grolla A, Taylor T, Kiso M, Kakugawa S, Gren J, Jones SM, Kawaoka Y, Feldmann H. Oseltamivir is effective against 1918 influenza virus infection of macaques but vulnerable to escape. mBio 10: e02059-19, 2019. (OCT 2019)
  6. Furusawa Y, Yamada S, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bekel H, Kawaoka Y. Influenza virus polymerase mutation stabilizes a foreign gene inserted into the virus genome by enhancing the transcription/replication efficiency of the nodified segment. mBio 10: e01794-19, 2019. (OCT 2019)
  7. Sakai-Tagawa Y, Yamayoshi S, Kawaoka Y. Sensitivity of commercially available influenza rapid diagnostic tests in the 2018-2019 influenza season. Front Microbiol 10: 2342, 2019. (OCT 2019)
  8. Ujie M, Takada K, Kiso M, Sakai-Tagawa Y, Ito M, Nakamura K, Watanabe S, Imai M, Kawaoka Y. Long-term culture of human lung adenocarcinoma A549 cells enhances the replication of human influenza A viruses. J Gen Virol 100: 1345-1349, 2019. (OCT 2019) 
  9. Yamada S, Yasuhara A, Kawaoka Y. Soluble recombinant hemagglutinin protein of H1N1pdm09 influenza virus elicits cross-protection against a lethal H5N1 challenge in mice. Front Microbiol 10: 2031, 2019. (SEP 2019) 
  10. Feng H, Nakajima N, Wu L, Yamashita M, Lopes TJS, Tsuji M, Hasegawa H, Watanabe T, Kawaoka Y. A glycolipid adjuvant, 7DW8-5, enhances the protective immune response to the current split influenza vaccine in mice. Front Microbiol 10: 2157, 2019. (SEP 2019) 
  11. Feng H, Yamashita M, Wu L, Lopes TJS, Watanabe T, Kawaoka Y. Food additives as novel influenza vaccine adjuvants. Vaccines 7: 127, 2019. (SEP 2019) 
  12. Liang L, Jiang L, Li J, Zhao Q, Wang J, He X, Huang S, Wang Q, Zhao Y, Wang G, Sun N, Deng G, Shi J, Tian G, Zeng X, Jiang Y, Liu L, Liu J, Chen P, Bu Z, Kawaoka Y, Chen H, Li C. Low polymerase activity attributed to PA drives the acquisition of the PB2 E627K mutation of H7N9 avian influenza virus in mammals. MBio 10: e01162-19, 2019. (JUN 2019)
  13. Zhong G, Fan S, Lopes TJS, Le MQ, van Bakel H, Dutta J, Smith GJD, Jayakumar J, Nguyen HLK, Hoang PVM, Halfmann P, Hatta M, Su YCF, Neumann G, Kawaoka Y. Isolation of highly pathogenic H5N1 influenza viruses in 2009-2013 in vietnam. Front Microbiol 10: 1411, 2019. (JUN 2019)
  14. Okuda M, Yamayoshi S, Uraki R, Ito M, Hamabata T, Kawaoka Y. Subclade 2.2.1-specific human monoclonal antibodies that recognize an epitope in antigenic site A of influenza A(H5) virus HA detected between 2015 and 2018. Viruses 11: E321, 2019. (APR 2019)
  15. Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, Shimizu K, Takasaki S, Sakai-Tagawa Y, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Yamada S, Watanabe T, Imai M, Kawaoka Y. A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses. Nat Microbiol 4: 1268-1273, 2019. (APR 2019)
  16. Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Koga M, Adachi E, Kikuchi T, Wang IH, Yamada S, Kawaoka Y. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus. Nat Microbiol 4:1024-1034, 2019. (MAR 2019)
  17. Oishi K, Yamayoshi S, Kawaoka Y. Identification of amino acid residues in influenza A virus PA-X That contribute to enhanced shutoff activity. Front Microbiol 10: 432, 2019. (MAR 2019)
  18. Kawakami C, Yamayoshi S, Akimoto M, Nakamura K, Miura H, Fujisaki S, Pattinson DJ, Shimizu K, Ozawa H, Momoki T, Saikusa M, Yasuhara A, Usuku S, Okubo I, Toyozawa T, Sugita S, Smith DJ, Watanabe S, Kawaoka Y. Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons. Euro Surveill 24: 1800467, 2019. (FEB 2019)
  19. Ito M, Yamayoshi S, Murakami K, Saito K, Motojima A, Nakaishi K, Kawaoka Y. Viruses. Characterization of mouse monoclonal antibodies against the HA of A(H7N9) influenza virus. Viruses 11: E149, 2019. (FEB 2019)
  20. Feng H, Yamashita M, da Silva Lopes TJ, Watanabe T, Kawaoka Y. Injectable excipients as novel influenza vaccine adjuvants. Front Microbiol 10: 19, 2019. (JAN 2019)
  21. Gu C, Zeng X, Song Y, Li Y, Liu L, Kawaoka Y, Zhao D, Chen H. Glycosylation and an amino acid insertion in the head of hemagglutinin independently affect the antigenic properties of H5N1 avian influenza viruses. Sci China Life Sci 62: 76-83, 2019. (JAN 2019)

2018

  1. Yamayoshi S, Yasuhara A, Ito M, Uraki R, Kawaoka Y. Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus. J Clin Virol 108: 105-111, 2018. (NOV 2018)
  2. Yasuhara A, Yamayoshi S, Ito M, Kiso M, Yamada S, Kawaoka Y. Isolation and characterization of human monoclonal antibodies that recognize the influenza A(H1N1)pdm09 virus hemagglutinin receptor-binding site and rarely yield escape mutant viruses. Front Microbiol 9: 2660, 2018. (NOV 2018)
  3. Hatta M, Zhong G, Chiba S, Lopes TJS, Neumann G, Kawaoka Y. Effectiveness of whole, inactivated, low pathogenicity influenza A(H7N9) vaccine against antigenically distinct, highly pathogenic H7N9 virus. Emerg Infect Dis 24:1910-1913, 2018. (OCT 2018)
  4. Chiba S, Hill-Batorski L, Neumann G, Kawaoka Y. The cellular DExD/H-Box RNA helicase UAP56 co-localizes with the influenza A virus NS1 protein. Front Microbiol 9: 2192, 2018. (SEP 2018)
  5. Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA. Recurring and adaptable binding motifs in broadly neutralizing antibodies to influenza virus are encoded on the D3-9 segment of the Ig gene. Cell Host Microbe 24: 569-578, 2018. (OCT 2018)
  6. Imai H, Dinis JM, Zhong G, Moncla LH, Lopes TJS, McBride R, Thompson AJ, Peng W, Le MTQ, Hanson A, Lauck M, Sakai-Tagawa Y, Yamada S, Eggenberger J, O'Connor DH, Suzuki Y, Hatta M, Paulson JC, Neumann G, Friedrich TC, Kawaoka Y. Diversity of influenza A(H5N1) Viruses in infected humans, Northern Vietnam, 2004-2010. Emerg Infect Dis 24: 1128-1238, 2018. (JUL 2018)
  7. Ueki H, Wang IH, Fukuyama S, Katsura H, da Silva Lopes TJ, Neumann G, Kawaoka Y. In vivo imaging of the pathophysiological changes and neutrophil dynamics in influenza virus-infected mouse lungs. Proc Natl Acad Sci U S A 115: E6622-E6629, 2018. (JUL 2018)
  8. Oishi K, Yamayoshi S, Kozuka-Hata H, Oyama M, Kawaoka Y. N-terminal acetylation by NatB is required for the shutoff activity of influenza A virus PA-X. Cell Rep 24(4): 851-860, 2018. (JUL 2018)
  9. Furusawa Y, Yamada S, Kawaoka Y. Host factor nucleoporin 93 is involved in the nuclear export of influenza virus RNA. Front Microbiol 9: 1675, 2018. (JUL 2018)
  10. Iwatsuki-Horimoto K, Shi J, Wang X, Sakai-Tagawa Y, Ito M, Murakami K, da Silva Lopes TJ, Nakaishi K, Yamayoshi S, Watabe S, Chen H, Kawaoka Y. Development of an influenza rapid diagnostic kit specific for the H7 subtype. Front Microbiol 9: 1346, 2018. (JUN 2018)
  11. Sammaibashi S, Yamayoshi S, Kawaoka Y. Strain-specific contribution of eukaryotic elongation factor 1 gamma to the translation of influenza A virus proteins. Front Microbiol 9: 1446, 2018. (JUN 2018)
  12. Iwatsuki-Horimoto K, Nakajima N, Kiso M, Takahashi K, Ito M, Inoue T, Horiuchi M, Okahara N, Sasaki E, Hasegawa H, Kawaoka Y. The marmoset as an animal model of influenza: infection with A(H1N1)pdm09 and highly pathogenic A(H5N1) viruses via the conventional or tracheal spray route. Front Microbiol 9: 844, 2018. (MAY 2018)
  13. Matsui K, Ozawa M, Kiso M, Yamashita M, Maekawa T, Kubota M, Sugano S, Kawaoka Y. Stimulation of alpha2-adrenergic receptors impairs influenza virus infection. Sci Rep 8: 4631, 2018. (MAR 2018)
  14. Soni P, Yasuhara A, Takenaga T, Iwatsuki-Horimoto K, Uraki R, Ito M, Sasaki T, Ikuta K, Yamayoshi S, Kawaoka Y. Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus. J Vet Med Sci 80: 1020-1024, 2018. (JUN 2018)
  15. Maemura T, Fukuyama S, Sugita Y, Lopes TJS, Nakao T, Noda T, Kawaoka Y. Lung-derived exosomal miR-483-3p regulates the innate immune response to influenza virus infection. J Infect Dis 217: 1372-1382, 2018. (APR 2018)
  16. Yamayoshi S, Kiso M, Yasuhara A, Ito M, Shu Y, Kawaoka Y. Enhanced replication of highly pathogenic influenza A(H7N9) virus in humans. Emerg Infect Dis 24: 746-750, 2018. (APR 2018)
  17. Watanabe T, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Takahashi K, Lops TJS, Ito M, Fukuyama S, Hasegawa H, Kawaoka Y. Experimental infection of Cynomolgus Macaques with highly pathogenic H5N1 influenza virus through the aerosol route. Sci Rep 8: 4801, 2018. (MAR 2018)
  18. Kiso M, Lopes TJS, Yamayoshi S, Ito M, Yamashita M, Nakajima N, Hasegawa H, Neumann G, Kawaoka Y. Combination therapy with neuraminidase and polymerase inhibitors in nude mice infected with influenza virus. J Infect Dis 217: 887-896, 2018. (MAR 2018)
  19. Iwatsuki-Horimoto K, Nakajima N, Ichiko Y, Sakai-Tagawa Y, Noda T, Hasegawa H, Kawaoka Y. Syrian hamster as an animal model for the study of human influenza virus infection. J Virol 92: e01693-17, 2018. (JAN 2018)
  20. Zhong G, Le MQ, Lopes TJS, Halfmann P, Hatta M, Fan S, Neumann G, Kawaoka Y. Mutations in the PA protein of avian H5N1 influenza viruses affect polymerase activity and mouse virulence. J Virol 92: e01557-17, 2018. (JAN 2018)
  21. Yamayoshi S, Ito M, Uraki R, Sasaki T, Ikuta K, Kawaoka Y. Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human. J Infect, in press. J Infect 76: 177-185, 2018. (FEB 2018)
  22. Oishi K, Yamayoshi S, Kawaoka Y. Identification of novel amino acid residues of influenza virus PA-X that are important for PA-X shutoff activity by using yeast. Virology 516: 71-75, 2018. (JAN 2018)
  23. Hatta M, Zhong G, Gao Y, Nakajima N, Fan S, Chiba S, Deering KM, Ito M, Imai M, Kiso M, Nakatsu S, Lopes TJ, Thompson AJ, McBride R, Suarez DL, Macken CA, Sugita S, Neumann G, Hasegawa H, Paulson JC, Toohey-Kurth KL, Kawaoka Y. Characterization of a feline influenza A(H7N2) virus. Emerg Infect Dis 24: 75-86, 2018. (JAN 2018)

2017

  1. Yasuhara A, Yamayoshi S, Soni P, Takenaga T, Kawakami C, Takashita E, Sakai-Tagawa Y, Uraki R, Ito M, Iwatsuki-Horimoto K, Sasaki T, Ikuta K, Yamada S, Kawaoka Y. Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. Sci Rep 7: 17735, 2017. (DEC 2017)
  2. Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, Hatta M, Yamada S, Ito M, Sakai-Tagawa Y, Shirakura M, Takashita E, Fujisaki S, McBride R, Thompson AJ, Takahashi K, Maemura T, Mitake H, Chiba S, Zhong G, Fan S, Oishi K, Yasuhara A, Takada K, Nakao T, Fukuyama S, Yamashita M, Lopes TJS, Neumann G, Odagiri T, Watanabe S, Paulson JC, Hasegawa H, Kawaoka Y. Characterization of a highly pathogenic avian H7N9 influenza virus isolated from an infected human. Cell Host&Microbe 22: 615-626, 2017. (NOV 2017)
  3. Sakai-Tagawa Y, Yamayoshi S, Kawakami C, Le MQ, Uchida Y, Saito T, Nidom CA, Humaira I, Toohey-Kurth K, Arafa AS, Liu MT, Shu Y, Kawaoka Y. Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan. Sci Rep 7: 14483, 2017. (NOV 2017)
  4. Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, Ito M, Nakajima N, Yamada S, Imai M, Kawakami E, Tomita Y, Fukuyama S, Itoh Y, Ogasawara K, Lopes TJS, Watanabe T, Moncla LH, Hasegawa H, Friedrich TC, Neumann G, Kawaoka Y. Emergence of oseltamivir-resistant H7N9 influenza viruses in immunosuppressed cynomolgus macaques. J Infect Dis 216: 582-593, 2017. (SEP 2017)
  5. Ui H, Yamayoshi S, Uraki R, Kiso M, Oishi K, Murakami S, Mimori S, Kawaoka Y. Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus. Vaccine 35: 1892-1897, 2017. (APR 2017)
  6. Yamayoshi S, Uraki R, Ito M, Kiso M, Nakatsu S, Yasuhara A, Oishi K, Sasaki T, Ikuta K, Kawaoka Y. A Broadly reactive human anti-hemagglutinin stem monoclonal antibody that inhibits influenza A virus particle release. EBioMedicine 17: 182-191, 2017. (MAR 2017)
  7. Zhao D, Liang L, Wang S, Nakao T, Li Y, Liu L, Guan Y, Fukuyama S, Bu Z, Kawaoka Y, Chen H. Glycosylation of the HA protein of H5N1 influenza virus increases its virulence in mice by exacerbating the host immune response. J Virol 91: e02215-02216, 2017. (MAR 2017)
  8. Nakayama M, Itoh Y, Shichinohe S, Nakabayashi R, Ishigaki H, Sakoda Y, Le QM, Kawaoka Y, Kida H, Ogasawara K. Potential risk of repeated nasal vaccination that induces allergic reaction with mucosal IgE and airway eosinophilic infiltration in cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus. Vaccine 35: 1008-1017, 2017. (FEB 2017)

2016

  1. Arafa A-S, Yamada S, Imai M, Watanabe T, Yamayoshi S, Iwatsuki-Horimoto K, Kiso M, Sakai-Tagawa Y, Ito M, Imamura T, Nakajima N, Takahashi K, Zhao D, Oishi K, Yasuhara A, Macken C, Zhong G, Hanson A, Fan S, Ping J, Hatta M, Lopes T, Suzuki Y, El-Husseiny M, Selim A, Hagag N, Soliman M, Neumann G, Hasegawa H, Kawaoka Y. Risk assessment of recent Egyptian H5N1 influenza viruses. Sci Rep 6:38388, 2016. (DEC 6, 2016EE/li>
  2. Ando T, Yamayoshi S, Tomita Y, Watanabe S, Watanabe T, Kawaoka Y. The host protein CLUH participates in the subnuclear transport of influenza virus ribonucleoprotein complexes. Nat Microbiol 1:16062, 2016. (AUG 2016)
  3. Li C, Hatta M, Burke DF, Ping J, Zhang Y, Ozawa M, Taft AS, Das SC, Hanson AP, Song J, Imai M, Wilker PR, Watanabe T, Watanabe S, Ito M, Iwatsuki-Horimoto K, Russell CA, James SL, Skepner E, Maher EA, Neumann G, Klimov A, Kelso A, McCauley J, Wang D, Shu Y, OdagiriT, Tashiro M, Xu X, Wentworth DE, Katz JM, Cox NJ, Smith DJ, Kawaoka Y. Selection of antigenically advanced variants of seasonal influenza viruses. Nat Microbiol 1:16058, 2016. (JUN 2016)
  4. Moncla LH, Zhong G, Nelson CW, Dinis JM, Mutschler J, Hughes AL, Watanabe T, Kawaoka Y, Friedrich TC. Selective bottlenecks shape evolutionary pathways taken during mammalian adaptation of a 1918-like avian influenza virus. Cell Host Microbe 19:169-180, 2016. (FEB 10, 2016)
  5. Katsura H, Fukuyama S, Watanabe S, Ozawa M, Neumann G, Kawaoka Y. Amino acid changes in PB2 and HA affect the growth of a recombinant influenza virus expressing a fluorescent reporter protein. Sci Rep 6:19933, 2016. (FEB 5, 2016)
  6. Yang H, Chen Y, Qiao C, He X, Zhou H, Sun Y, Yin H, Meng S, Liu L, Zhang Q, Kong H, Gu C, Li C, Bu Z, Kawaoka Y, Chen H. Prevalence, genetics, and transmissibility in ferrets of Eurasian avian-like H1N1 swine influenza viruses. Proc Natl Acad Sci USA 113:392-397, 2016. (JAN 2016)
  7. Yamayoshi S, Watanabe M, Goto H, Kawaoka Y. Identification of A Novel Viral Protein Expressed from the PB2 Segment of Influenza A Virus. J Virol 90:444-456, 2016. (JAN 2016)

2015

  1. Hanson A, Imai M, Hatta M, McBride R, Imai H, Taft A, Zhong G, Watanabe T, Suzuki Y, Neumann G, Paulson JC, Kawaoka Y. Identification of Stabilizing Mutations in an H5 HA Influenza Virus Protein. J Virol 90:2981-2992, 2015. (DEC 30, 2015)
  2. Zhao D, Fukuyama S, Sakai-Tagawa Y, Takashita E, Shoemaker JE, Kawaoka Y. C646, a novel p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, attenuates influenza A virus infection. Antimicrob Agents Chemother 60:1902-1906, 2015. (DEC 28, 2015)
  3. Uraki R, Piao Z, Akeda Y, Iwatsuki-Horimoto K, Kiso M, Ozawa M, Oishi K, Kawaoka Y. A bivalent vaccine based on a PB2-knockout influenza virus protects mice from secondary pneumococcal pneumonia. J Infect Dis 212:1939-1948, 2015. (DEC 15, 2015)
  4. Uraki R, Piao Z, Akeda Y, Iwatsuki-Horimoto K, Kiso M, Ozawa M, Oishi K, Kawaoka Y. A bivalent vaccine based on a PB2-knockout influenza virus protects mice from secondary pneumococcal pneumonia. J Infect Dis 212(12):1939-1948, 2015. (DEC 15, 2015)
  5. Forero A, Tisoncik-Go J, Watanabe T, Zhong G, Hatta M, Tchitchek N, Selinger C, Chang J, Barker K, Morrison J, Berndt JD, Moon RT, Josset L, Kawaoka Y, Katze MG. The 1918 PB2 protein enhances virulence through the disruption of inflammatory and Wnt-mediated signaling in mice. J Virol 90:2240-2253, 2015. (DEC 09, 2015)
  6. Zhao D, Fukuyama S, Yamada S, Lopes TJ, Maemura T, Katsura H, Ozawa M, Watanabe S, Neumann G, Kawaoka Y. Molecular determinants of virulence and stability of a reporter-expressing H5N1 influenza A virus. J Virol 89:11337-11346, 2015. (NOV 2015)
  7. Ping J, Lopes T.J.S, Nidom CA, Ghedin E, Macken CA, Fitch A, Imai M, Maher EA, Neumann G, Kawaoka Y. Development of high-yield influenza A virus vaccine viruses. Nat Commun 6:8148, 2015. (SEP 2015EE/li>
  8. Oishi K, Yamayoshi S, Kawaoka Y. Mapping of a region of the PA-X protein of influenza A virus that is important for its shut-off activity. J Virol 89:8661-8665, 2015. (AUG 2015)
  9. Shoemaker JE, Fukuyama S, Eisfeld AJ, Zhao D, Kawakami E, Sakabe S, Maemura T, Gorai T, Katsura H, Muramoto Y, Watanabe S, Watanabe T, Fuji K, Matsuoka Y, Kitano H, Kawaoka Y. An ultrasensitive mechanism regulates influenza virus-induced inflammation. PLoS Pathog e1004856, 2015. (JUN 2015)
  10. Taft AS, Ozawa M, Fitch A, Depasse JV, Halfmann PJ, Hill-Batorski L, Hatta M, Friedrich TC, Lopes TJS, Maher EA, Ghedin E, Macken CA, Neumann B, Kawaoka Y. Identification of mammalian-adapting mutations in the polymerase complex of an avian H5N1 influenza virus. Nat Commun 6:7491, 2015. (JUN 2015)
  11. Yamaji R, Yamada S, Le MQ, Li C, Chen H, Qurnianingsih E, Nidom CA, Ito M, Sakai-Tagawa Y, Kawaoka Y. Identification of PB2 mutations responsible for the efficient replication of H5N1 influenza viruses in human lung epithelial cells. J Virol 89:3947-3956, 2015. (APR 2015)
  12. Yamaji R, Yamada S, Le MQ, Ito M, Sakai-Tagawa Y, Kawaoka Y. Mammalian adaptive mutations of the PA protein of highly pathogenic avian H5N1 influenza virus. J Virol 89:4117-4125, 2015. (APR 2015)
  13. Fukuyama S, Katsura H, Zhao D, Ozawa M, Ando T, Shoemaker JE, Ishikawa I, Yamada S, Neumann G, Watanabe S, Kitano H, Kawaoka Y. Multi-spectral fluorescent reporter influenza viruses (Color-flu) as powerful tools for in vivo studies. Nat Commun, 6:6600, 2015.(MAR 2015)
  14. Yamayoshi S, Fukuyama S, Yamada S, Zhao D, Murakami S, Uraki R, Watanabe T, Tomita Y, Neumann G, Kawaoka Y. Amino acids substitutions in the PB2 protein of H7N9 influenza A viruses are important for virulence in mammalian hosts. Sci Rep 5:8039, 2015. (JAN 27, 2015)

2014

  1. Sakai-Tagawa Y, Ozawa M, Yamada S, Uchida Y, Saito T, Takahashi K, Sugaya N, Tashiro M, Kawaoka Y. Detection sensitivity of influenza rapid diagnostic tests. Microbiol Immunol 58:600-606, 2014.
  2. Fan S, Hatta M, Kim JH, Halfmann P, Imai M, Macken CA, Le MQ, Nguyen T, Neumann G, Kawaoka Y. Novel residues in avian influenza virus PB2 protein affect virulence in mammalian hosts. Nat Commun 5:5021, 2014.
  3. Fan S, Hatta M, Kim JH, Le MQ, Neumann G, Kawaoka Y. Amino Acid Changes in the Influenza A Virus PA Protein That Attenuate Avian H5N1 Viruses in Mammals. J Virol 88:13737-13746, 2014.
  4. Watanabe T, Zhong G, Russell CA, Nakajima N, Hatta M, Hanson A, McBride R, Burke DF, Takahashi K, Fukuyama S, Tomita Y, Maher A, Watanabe S, Imai M, Neumann G, Hasegawa H, Paulson JC, Smith DJ, Kawaoka Y. Circulating avian influenza viruses closely related to the 1918 virus have pandemic potential. Cell Host&Microbe 15:692-705, 2014.
  5. Muramoto Y, Shoemaker JE, Le MQ, Itoh Y, Tamura D, Sakai-Tagawa Y, Imai H, Uraki R, Takano R, Kawakami E, Ito M, Okamoto K, Ishigaki H, Mimuro H, Sasakawa C, Matsuoka Y, Noda T, Fukuyama S, Ogasawara K, Kitano H, Kawaoka Y. Disease Severity Is Associated with Differential Gene Expression at the Early and Late Phases of Infection in Nonhuman Primates Infected with Different H5N1 Highly Pathogenic Avian Influenza Viruses. J Virol 88:8981-8997, 2014.
  6. Itoh Y, Yoshida R, Shichinohe S, Higuchi M, Ishigaki H, Nakayama M, Pham VL, Ishida H, Kitano M, Arikata M, Kitagawa N, Mitsuishi Y, Ogasawara K, Tsuchiya H, Hiono T, Okamatsu M, Sakoda Y, Kida H, Ito M, Quynh Mai L, Kawaoka Y, Miyamoto H, Ishijima M, Igarashi M, Suzuki Y, Takada A. Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. PLoS Pathog. 10:e1004192, 2014.
  7. Uraki R, Das SC, Hatta M, Kiso M, Iwatsuki-Horimoto K, Ozawa M, Coban C, Ishii KJ, Kawaoka Y. Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine. Vaccine 32:5295-300, 2014.
  8. Liu Z, Kato A, Shindo K, Noda T, Sagara H, Kawaoka Y, Arii J, Kawaguchi Y. Herpes simplex virus 1 UL47 interacts with viral nuclear egress factors UL31, UL34 and Us3, and regulates viral nuclear egress. J Virol 88:4657-4667, 2014.
  9. Neumann G, Macken CA, Kawaoka Y. Identification of amino acid changes that may have been critical for the genesis of A(H7N9) influenza viruses. J Virol 88:4877-4896, 2014.
  10. Yamayoshi S, Yamada S, Fukuyama S, Murakami S, Zhao D, Uraki R, Watanabe T, Tomita Y, Macken C, Neumann G, Kawaoka Y. Virulence-affecting amino acid changes in the PA protein of H7N9 influenza A viruses. J Virol 88:3127-3134, 2014.

2013

  1. Nakayama M, Shichinohe S, Itoh Y, Ishigaki H, Kitano M, Arikata M, Pham VL, Ishida H, Kitagawa N, Okamatsu M, Sakoda Y, Ichikawa T, Tsuchiya H, Nakamura S, Le QM, Ito M, Kawaoka Y, Kida H, Ogasawara K. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine. PLoS One 8:e82740, 2013.
  2. Wilker PR, Dinis JM, Starrett G, Imai M, Hatta M, Nelson CW, O’Connor DH, Hughes AL, Neumann G, Kawaoka Y, Friedrich TC. Selection on haemagglutinin imposes a bottleneck during mammalian transmission of reassortant H5N1 influenza viruses. Nat Commun 4:2636, 2013.
  3. Imai M, Herfst S, Sorrell EM, Schrauwen EJ, Linster M, De Graaf M, Fouchier RA, Kawaoka Y. Transmission of influenza A/H5N1 viruses in mammals. Virus Res 178: 15-20, 2013.
  4. Takahashi T, Song J, Suzuki T, Kawaoka Y. Mutations in NA that induced low pH-stability and enhanced the replication of pandemic (H1N1) 2009 influenza A virus at an early stage of the pandemic. PLoS One 8:e64439, 2013.
  5. Deng G, Tan D, Shi J, Cui P, Jiang Y, Liu L, Tian G, Kawaoka Y, Li C, Chen H. Complex reassortment of multiple subtypes of avian influenza viruses in domestic ducks at the Dongting Lake region of China. J Virol 87:9452-9462, 2013.
  6. Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:551-555, 2013.
  7. Morita M, Kuba K, Ichikawa A, Nakayama M, Katahira J, Iwamoto R, Watanebe T, Sakabe S, Daidoji T, Nakamura S, Kadowaki A, Ohto T, Nakanishi H, Taguchi R, Nakaya T, Murakami M, Yoneda Y, Arai H, Kawaoka Y, Penninger JM, Arita M, Imai Y. The lipid mediator protectin d1 inhibits influenza virus replication and improves severe influenza. Cell 153:112-125, 2013.
  8. Kiso M, Takano R, Sakabe S, Katsura H, Shinya K, Uraki R, Watanabe S, Saito H, Toba M, Kohda N, Kawaoka Y. Protective efficacy of orally administered, heat-killed Lactobacillus pentosus b240 against influenza A virus. Sci Rep 3:1563, 2013.
  9. Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 18(15), 2013.
  10. Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E, Ozawa M, Kawaoka Y. A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges. J Virol 87:7874-7881, 2013.
  11. Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Sci Rep 3:1106, 2013.
  12. Fan S, Macken CA, Li C, Ozawa M, Goto H, Iswahyudi, Nidom CA, Chen H, Neumann G, Kawaoka Y. Synergistic effect of the PDZ and the p85β-binding domains of the NS1 protein in virulence of an avian H5N1 influenza A virus. J Virol 87:4861-4871, 2013.
  13. Watanabe T, Tisoncik-Go J, Tchitchek N, Watanabe S, Benecke AG, Katze MG, Kawaoka Y. 1918 HA and the viral RNA polymerase complex enhance viral pathogenicity, but only HA induces aberrant host responses in mice. J Virol 87:5239-5254, 2013.
  14. Uraki R, Kiso M, Shinya K, Goto H, Takano R, Iwatsuki-Horimoto K, Takahashi K, Daniels RS, Hungnes O, Watanabe T, Kawaoka Y. Virulence determinants of pandemic A(H1N1)2009 virus in a mouse model. J Virol 87:2226-2233, 2013.
  15. Muramoto Y, Noda T, Kawakami E, Akkina R, Kawaoka Y. Identification of novel influenza A virus proteins translated from PA mRNA. J Virol 87:2344-2362, 2013.
  16. Sakabe S, Takano R, Nagamura-Inoue T, Yamashita N, Nidom CA, Quynh Le MT, Iwatsuki-Horimoto K, Kawaoka Y. Differences in cytokine production in human macrophages and in virulence in mice are attributable to the acidic polymerase protein of highly pathogenic influenza A virus subtype H5N1. J Infect Dis 207: 262-271, 2013.
  17. Takano R, Kiso M, Igarashi M, Le QM, Sekijima M, Ito K, Takada A, Kawaoka Y. Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the NA of H5N1 avian influenza viruses. J Infect Dis 207: 89-97, 2013.

2012

  1. Takahashi T, Nidom CA, Quynh Le MT, Suzuki T, Kawaoka Y. Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase. FEBS Open Bio 2:261-265, 2012.
  2. Shoemaker JE, Fukuyama S, Eisfeld AJ, Muramoto Y, Watanabe S, Watanabe T, Matsuoka Y, Kitano H, Kawaoka Y. Integrated network analysis reveals a novel role for the cell cycle in 2009 pandemic influenza virus-induced inflammation in macaque lungs. BMC Syst Biol 6:117, 2012.
  3. Das SC, Hatta M, Wilker PR, Myc A, Hamouda T, Neumann G, Baker JR Jr, Kawaoka Y. Nanoemulsion W(80)5EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 30:6871-6877, 2012.
  4. Imai M, Watanabe S, Kawaoka Y. The cytoplasmic tail domain of influenza B virus hemagglutinin is important for its incorporation into virions but is not essential for virus replication in cell culture in the presence of compensatory mutations. J Virol 86:11633-11644, 2012.
  5. Shimojima M, Kawaoka Y. Cell surface molecules involved in infection mediated by lymphocytic choriomeningitis virus gycoprotein. J Vet Med Sci 74:1363-1366, 2012.
  6. Shimojima M, Stroher U, Ebihara H, Feldmann H, Kawaoka Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol 86: 2067-2078, 2012.
  7. Victor ST, Watanabe S, Katsura H, Ozawa M, Kawaoka Y. A replication-incompetent PB2-knockout influenza A virus vaccine vector. J Virol 86: 4123-4128, 2012.
  8. Nidom CA, Yamada S, Nidom RV, Rahmawati K, Alamudi MY, Kholik, Indrasari S, Hayati RS, Iwatsuki Horimoto K, Kawaoka Y. Genetic characterization of H5N1 influenza viruses isolated from chickens in Indonesia in 2010. Virus Genes 44: 459-465, 2012.
  9. Shinya K, Gao Y, Cilloniz C, Suzuki Y, Fujie M, Deng G, Zhu Q, Fan S, Makino A, Muramoto Y, Fukuyama S, Tamura D, Noda T, Eisfeld AJ, Katze MG, Chen H, Kawaoka Y. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol 86: 6055-6066, 2012.
  10. Kikuchi T, Iwatsuki-Horimoto K, Adachi E, Koga M, Nakamura H, Hosoya N, Kawana-Tachikawa A, Koibuchi T, Miura T, Fujii T, Kawaoka Y, Iwamoto A. Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 influenza vaccine in HIV-1-positive adults. Vaccine 30: 3819-3823, 2012.
  11. Watanabe T, Imai M, Watanabe S, Shinya K, Hatta M, Li C, Neumann G, Ozawa M, Hanson A, Zhong G, Fukuyama S, Kawakami E, Simmons HA, Schenkman D, Brunner K, Capuano SV 3rd, Weinfurter JT, Kilander A, Dudman SG, Suresh M, Hungnes O, Friedrich TC, Kawaoka Y. Characterization in vitro and in vivo of pandemic (H1N1) 2009 viruses isolated from patients. J Virol 86: 9361-9368, 2012.
  12. Zhang Y, Zhang Q, Gao Y, He X, Kong H, Jiang Y, Guan Y, Xia X, Shu Y, Kawaoka Y, Bu Z, Chen H. Key molecular factors in HA and PB2 contribute to the efficient transmission of the 2009 H1N1 pandemic influenza virus. J Virol 86: 9666-9674, 2012.
  13. Inagaki A, Goto H, Kakugawa S, Ozawa M, Kawaoka Y. Competitive incorporation of homologous gene segments of influenza A virus into virions. J Virol 86: 10200-10202, 2012.
  14. Yamada S, Shinya K, Takada A, Ito T, Suzuki T, Suzuki Y, Me QM, Ebina M, Kasai N, Kida H, Horimoto T, Rivailler P, Chen LM, Donis RO, Kawaoka Y. Adaptation of a duck influenza A virus in quail. J Virol 86:1411-1420, 2012.
  15. Das SC, Watanabe S, Hatta M, Noda T, Neumann G, Ozawa M, Kawaoka Y. The highly conserved arginine residues at positions 76 through 78 of influenza A virus matrix protein M1 play an important role in viral replication by affecting the intracellular localization of M1. J Virol 86:1522-1530, 2012.
  16. Shi J, Wen Z, Guo J, Zhang Y, Deng G, Shu Y, Wang D, Jiang Y, Kawaoka Y, Bu Z, Chen H. Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice. Antiviral Res 93:346-353, 2012.
  17. Noda T, Sugita Y, Aoyama K, Hirose A, Kawakami E, Miyazawa A, Sagara H, Kawaoka Y. Three-dimensional analysis of ribonucleoprotein complexes in influenza A virus. Nat Commun 3:639, 2012.
  18. Ginting TE, Shinya K, Kyan Y, Makino A, Matsumoto N, Kaneda S, Kawaoka Y. Amino acid changes in hemagglutinin contribute to the replication of osertamivir-resistant H1N1 influenza viruses. J Virol 86:121-127, 2012.
  19. Shinya K, Ito M, Makino A, Tanaka M, Miyake K, Eisfeld AJ, Kawaoka Y. The TLR4-TRIF pathway protects against H5N1 influenza virus infection. J Virol 86:19-24, 2012.
  20. Murakami S, Horimoto T, Ito M, Takano R, Katsura H, Shimojima M, Kawaoka Y. Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion. J Virol 86:1405-1410, 2012.

2011

  1. Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, Ge J, Kawaoka Y, Bu Z, Chen H. A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J Virol 85:10989-10998, 2011.
  2. Watanabe T, Shinya K, Watanabe S, Imai M, Hatta M, Li C, Wolter BF, Neumann G, Hanson A, Ozawa M, Yamada S, Imai H, Sakabe S, Takano R, Iwatsuki-Horimoto K, Kiso M, Ito M, Fukuyama S, Kawakami E, Gorai T, Simmons HA, Schenkman D, Brunner K, Capuano SV 3rd, Weinfurter JT, Nishio W, Maniwa Y, Igarashi T, Makino A, Travanty EA, Wang J, Kilander A, Dudman SG, Suresh M, Mason RJ, Hungnes O, Friedrich TC, Kawaoka Y. Avian-type receptor-binding ability can increase influenza virus pathogenicity in macaques. J Virol 85:13195-13203, 2011.
  3. Octaviani CP, Goto H, Kawaoka Y. Reassortment between seasonal H1N1 and pandemic (H1N1) 2009 influenza viruses is restricted by limited compatibility among polymerase subunits. J Virol 85:8449-8452, 2011.
  4. Horimoto T, Maeda K, Murakami S, Kiso M, Iwatsuki-Horimoto K, Sashika M, Ito T, Suzuki K, Yokoyama M, Kawaoka Y. Highly pathogenic avian influenza virus infection in feral raccoons, Japan. Emerging Infectious Diseases 17:714-717, 2011.
  5. Shimizu K, Li C, Muramoto Y, Yamada S, Arikawa J, Chen H, Kawaoka Y. The NP and M segments of H5N1 influenza viruses are responsible for dominance in embryonated eggs. J Gen Virol 92:1645-1649, 2011.
  6. Shinya K, Makino A, Tanaka H, Hatta M, Watanabe T, Le MQ, Imai H, Kawaoka Y. Systemic dissemination of H5N1 influenza A viruses in ferrets and hamsters after direct intragastric inoculation. J Virol 85:4673-4678, 2011.
  7. Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, Hatta Y, Gao P, Ozawa M, Le QM, Kawaoka Y. Subclinical brain injury caused by H5N1 influenza virus infection. J Virol 85:5202-5207, 2011.
  8. Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, Ginting TE, Makino A, Eisfeld AJ, Kawaoka Y. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol J 8:97, 2011.
  9. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le MT, Nagamura-Inoue T, Horimoto T, Yamashita N, Kawaoka Y. Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses. J Gen Virol 92:1428-1434, 2011.
  10. Kiso M, Ozawa M, Le MT, Imai H, Takahashi K, Kakugawa S, Noda T, Horimoto T, Kawaoka Y. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J Virol 85:4667-4672, 2011.
  11. Iwatsuki-Horimoto K, Horimoto T, Tamura D, Kiso M, Kawakami E, Hatakeyama S, Ebihara Y, Koibuchi T, Fujii T, Takahashi K, Shimojima M, Sakai-Tagawa Y, Ito M, Sakabe S, Iwasa A, Takahashi K, Ishii T, Gorai T, Tsuji K, Iwamoto A, Kawaoka Y. Sero-prevalence of pandemic (H1N1) 2009 Influenza A Virus among schoolchildren and their parents in Tokyo, Japan. Clin Vaccine Immunol 18:860-866, 2011.
  12. Ozawa M, Basnet S, Burley LM, Neumann G, Hatta M, Kawaoka Y. Impact of amino acid mutations in PB2, PB1-F2, and NS1 on the replication and pathogenicity of pandemic (H1N1) 2009 influenza viruses. J Virol 85:4596-5601, 2011.
  13. Tamura D, Sugaya N, Ozawa M, Takano R, Ichikawa M, Yamazaki M, Kawakami C, Shimizu H, Uehara R, Kiso M, Kawakami E, Mitamura K, Kawaoka Y. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 52:432-437, 2011.
  14. Hatakeyama S, Iwatsuki-Horimoto K, Okamoto K, Nukui Y, Yata N, Fujita A, Inaba S, Yotsuyanagi H, Kawaoka Y. Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults. Vaccine 29:9224-9228, 2011.
  15. Ozawa M, Victor ST, Taft AS, Yamada S, Li C, Hatta M, Das SC, Takashita E, Kakugawa S, Maher EA, Neumann G, Kawaoka Y. Replication-incompetent influenza A viruses that stably express a foreign gene. J Gen Virol 92(Pt 12):2879-2888, 2011.
  16. Sakabe S, Ozawa M, Takano R, Iwatsuki-Horimoto K, Kawaoka Y. Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res 158:124-129, 2011.
  17. Yamaoka M, Palilingan JF, Wibisono J, Yudhawati R, Nidom RV, Alamudi MY, Ginting TE, Makino A, Nidom CA, Shinya K, Kawaoka Y. Virological surveillance of human influenza in Indonesia, October 2008-March 2010. Microbiol Immunol 55:514-517, 2011.
  18. Poetranto ED, Yamaoka M, Nastri AM, Krisna LA, Rahman MH, Wulandari L, Yudhawati R, Ginting TE, Makino A, Shinya K, Kawaoka Y. An H5N1 highly pathogenic avian influenza virus isolated from a local tree sparrow in Indonesia. Microbiol Immunol 55:666-672, 2011.
  19. Song J, Feng H, Xu J, Zhao D, Shi J, Li Y, Deng G, Jiang Y, Li X, Zhu P, Guan Y, Bu Z, Kawaoka Y, Chen H. The PA protein directly contributes to the virulence of H5N1 avian influenza viruses in domestic ducks. J Virol 85:2180-2188, 2011.

2010

  1. Chen Y, Zhong G, Wang G, Deng G, Li Y, Shi J, Zhang Z, Guan Y, Jiang Y, Bu Z, Kawaoka Y, Chen H. Dogs are highly susceptible to H5N1 avian influenza virus. Virology 405:15-19, 2010.
  2. Nidom CA, Takano R, Yamada S, Sakai-Tagawa Y, Daulay S, Aswadi D, Suzuki T, Suzuki Y, Shinya K, Iwatsuki-Horimoto K, Muramoto Y, Kawaoka Y. H5N1 influenza viruses from pigs in Indonesia. Emerg Inf Dis 16:1515-1523, 2010.
  3. Le QM, Ito M, Muramoto Y, Hoang PV, Vuong CD, Sakai-Tagawa Y, Kiso M, Ozawa M, Takano R, Kawaoka Y. Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans from 2003 to 2008 in Northern Vietnam. J Gen Virol 91:2485-2490, 2010.
  4. Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le MQ, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa M, Kawaoka Y. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res 88:249-255, 2010.
  5. Hatta Y, Hershberger K, Shinya K, Dubielzig RR, Hatta M, Kawaoka Y, Suresh M. Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathogens 6:e1001139, 2010.
  6. Imai H, Shinya K, Takano R, Kiso M, Muramoto Y, Sakabe S, Murakami S, Ito M, Yamada S, Le MQ, Nidom CA, Sakai-Tagawa Y, Takahashi K, Omori Y, NodaT, Shimojima M, Kakugawa S, Goto H, Iwatsuki-Horimoto K, Horimoto T, Kawaoka Y. The HA and NS genes of human H5N1 influenza A virus contribute to high virulence in ferrets. PLoS Pathogens 6:e1001106, 2010.
  7. Octaviani CP, Ozawa M, Yamada S, Goto H, Kawaoka Y. High genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J Virol 84:10918-10922, 2010.
  8. Yamada S, Hatta M, Staker BL, Watanabe S, Imai M, Shinya K, Sakai-Tagawa Y, Ito M, Ozawa M, Watanabe T, Sakabe S, Li C, Kim JH, Myler PJ, Phan I, Raymond A, Smith E, Stacy R, Nidom CA, Lank SM, Wiseman RW, Bimber BN, O’Connor DH, Neumann G, Stewart LJ, Kawaoka Y. Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathogens 6:e1001034, 2010
  9. Sakai-Tagawa Y, Ozawa M, Tamura D, Le QM, Nidom CA, Sugaya N, Kawaoka Y. Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol 48:2872-2877, 2010.
  10. Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, Kawaoka Y. A mutation in H5 haemagglutinin that conferred human receptor recognition is not maintained stably during duck passage. J Gen Virol 91:1461-1463, 2010.
  11. Li C, Hatta M, Nidom CA, Muramoto Y, Watanabe S, Neumann G, Kawaoka Y. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence Proc Natl Acad Sci USA 107:4687-4692, 2010.
  12. Kim JH, Hatta M, Watanabe S, Neumann G, Watanabe T, Kawaoka Y. Role of host-specific amino acids in the pathogenicity of avian H5N1 influenza viruses in mice J Gen Virol 91:1284-1289, 2010.
  13. Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, Yamashita M, Kawaoka Y. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses Plos Patho 6: e1000786, 2010.
  14. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses Proc Natl Acad Sci USA 107:882-887, 2010.

2009

  1. Fan S, Gao Y, Shinya K, Li CK, Li Y, Shi J, Jiang Y, Suo Y, Taong T, Zhong G, Song J, Zhang Y, Tian G, Guan Y, Xu X-N, Bu Z, Kawaoka Y, Chen H Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates Plos Patho 5:e1000409, 2009.
  2. Gao Y, Zhang Y, Shinya K, Deng G, Jiang Y, Li Z, Guan Y, Tian G, Li Y, Shi J, Liu L, Zeng X, Bu Z, Xia X, Kawaoka Y, Chen H. Identification of Amino Acids in HA and PB2 Critical for the Transmission of H5N1 Avian Influenza Viruses in a Mammalian Host Plos Patho 5:e1000709, 2009.
  3. Shinya K, Makino A, Ozawa M, Kim JH, Sakai-Tagawa Y, Ito M, Le QM, Kawaoka Y. Ostrich involvement in the selection of H5N1 influenza virus possessing mammalian-type amino acids in PB2 J Virol 83:13015-13018, 2009.
  4. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Meumann G, Gern J, Kida H, Ogawsawara K & Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025, 2009.
  5. Takano R, Nidom CA, Kiso M, Muramoto Y, Yamada S, Shinya K, Sakai-Tagawa Y, Kawaoka Y. A comparison of the pathogenicity of avian and swine H5N1 influenza viruses in Indonesia. Arch Virol 154:677-681, 2009.
  6. Watanabe S, Watanabe T, Kawaoka Y Influenza A virus lacking M2 protein as a live attenuated vaccine J Virol 83:5947-5950, 2009.
  7. Halfmann P, Ebihara H, Marzi A, Hatta Y, Watanabe S, Suresh M, Neumann G, Feldmann H, Kawaoka Y. Replication-Deficient Ebolavirus as a Vaccine Candidate. J Virol 83:3810-3815, 2009.
  8. Li Z, Watanabe T, Hatta M, Watanabe S, Nanbo A, Ozawa M, Kakugawa S, Shimojima M, Yamada S, Neumann G, Kawaoka Y. Mutational analysis of conserved amino acids in the influenza A virus nucleoprotein. J Virol 83:4153-4162, 2009.
  9. Le QM, Sakai-Tagawa Y, Ozawa M, Ito M, Kawaoka Y. Selection of H5N1 influenza virus PB2 during replication in human J Virol 83:5278-5281, 2009.
  10. Fan S, Deng G, Song J, Tian G, Suo Y, Jiang Y, Guan Y, Bu Z, Kawaoka Y, Chen H. Two amino acid residues in the matrix protein M1 contribute to the virulence difference of H5N1 avian influenza viruses in mice Virology 384:28-32, 2009.

2008

  1. Li C, Hatta M, Watanabe S, Neumann G, Kawaoka Y. Compatibility among polymerase subunit proteins is a restricting factor in reassortment between equine H7N7 and human H3N2 influenza viruses J virol 82:11880-11888, 2008.
  2. Jia B, Shi J, Li Y, Shinya K, Muramoto Y, Zeng X, Tian G, Kawaoka Y, Chen H. Pathogenicity of Chinese H5N1 highly pathogenic avian influenza viruses in pigeons. Arch Virol 153:1821-1826, 2008.
  3. Murakami S, Iwasa A, Iwatasuki-Horimoto K, Ito M, Kiso M, Kida H, Takada A, Midon CA, Mai LQ, Yamada S, Imai H, Sakai-Tagawa Y, Kawaoka Y, Horimoto T. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine 26:6398-6404, 2008.
  4. Murakami S, Horimoto T, Mai LQ, Nidom CA, Chen H, Muramoto Y, Yamada S, Iwasa A Iwatsuki-Horimoto K, Shimojima M, Iwata A, Kawaoka Y. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. Journal of Virology 82:10502-10509, 2008.
  5. Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, Newton MA, Ahlquist P, Kawaoka Y. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454:890-893, 2008.
  6. Iwatsuki-Horimoto K, Hatta Y, Hatta M, Muramoto Y, Chen H, Kawaoka Y, Horimoto T. Limited compatibility between the RNA polymerase components of influenza virus type A and B Virus Res 135:161-165, 2008.
  7. Jiao P, Tian G, Li Y, Liu C, Liu W, Deng G, Guan Y, Bu Z, Kawaoka Y, Chen H. A single amino acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice Journal of Virology 82:1146-1154, 2008.
  8. Murakami S, Horimoto T, Yamada S, Kakugawa S, Goto H, Kawaoka Y. Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J Virol 82:1605-1609, 2008.
  9. Zhu Q, Yang H, Deng G, Yu K, Bu Z, Kawaoka Y, Chen H. A naturally occurring deletion in its NS gene contributes to attenuation of an H5N1 swine influenza virus in chickens. Journal of Virology 82:220-228, 2008.

2007

  1. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Kawaoka Y. Growth of H5N1 influenza A viruses in the upper resporatory tracts of mice. Plos Pathogens 3: 1374-1379, 2007.

2006

  1. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, Muramoto Y, Ito M, Kiso M, HorimotoT, Shinya K, Sawada T, Kiso M, Usui T, Murata T, Lin Y, Hay A, Haire LF, Stevens DJ, Russell RJ, Gamblin SJ, Skehel JJ, Kawaoka Y. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444:378-382, 2006.
  2. Chen H, Li Y, Li Z, Shi J, Shinya K, Deng G, Qi Q, Tian G, Fan S, Zhao H, Sun Y, Kawaoka Y. Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China. Journal of Virology:80, 5976-5983, 2006.
  3. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Influenza virus receptors in the human airway. Nature 440:435-436, 2006.

2005

  1. Le QM, Kiso M, Someya K, Sakai YT, NguyenTH, Nguyen KHL, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. Emergence of an oseltamivir-resistant H5N1 influenza A virus. Nature 437:1108, 2005.

学会発表

2018

  1. The role of N-terminal acetylation by NatB in the shutoff activity of PA-X. Yamayoshi S. The 7th China-Japan Bilateral Symposium on All Influenza Viruses. æ·±圳ã€ä¸­å›½ã€E018/11/2, (Oral).
  2. Characterization of a highly pathogenic avian H7N9 influenza virus. Imai M. IMSUT-CAS Workshop on Infectious Diseases 2018, æ±äº¬, 2018/10/9, (Oral).
  3. Identification of amino acids that enhance virus replication in mammalian hosts in the PB2 and PA proteins of a highly pathogenic H7N9 influenza virus isolated from a human. Yamayoshi S, Kiso M, Yasuhara A, Ito M, Kawaoka Y. 8th Orthomyxovirus research conference, ãƒãƒŽã‚¤, ベトナム, 2018/9/12-14, (Oral).
  4. Identification of amino acids that enhance virus replication in mammalian hosts in the PB2 and PA proteins of a highly pathogenic H7N9 influenza virus isolated from a human. Yamayoshi S, Kiso M, Yasuhara A, Ito M, Kawaoka Y. 17th Negative Strand Virus Meeting 2018, ベローãƒE イタリア, 2018/6/17-22, (Poster).
  5. スペインã‹ãœå¤§æµè¡E00å¹´ã€ãã®ã‚¤ãƒ³ãƒ‘クトã¨ã‚¦ã‚¤ãƒ«ã‚¹ã®è§£æžE 今井正樹. 第92回日本感染ç—E­¦ä¼šå­¦è¡“講演会 第66回日本化学療法学会ç·ä¼šåˆåŒå­¦ä¼šã€€ç‰¹åˆ¥ä¼ç”»ã€€ã‚¹ãƒšã‚¤ãƒ³ã‹ãœå¤§æµè¡E00周年記念講æ¼E 岡山, 2018/6/1, (Oral).
  6. Human monoclonal antibodies against influenza virus. Yamayoshi S, Kawaoka Y. MEDLAB Asia Pacific & Asia Health Exhibition & Congress 2018, シンガãƒãEル, 2018/4/2-4, (Oral).
  7. Human monoclonal anti-HA stem neutralizing and non-neutralizing antibodies protect against influenza A virus infection. Yamayoshi S, Ito M, Uraki R, Kawaoka Y. Keystone Symposia, Antibodies as Drugs: Translating Molecules into Treatments (C1), ウィスラー, カナダ, 2018/2/25-3/1, (Poster).
  8. 中国ã§ç™ºç”Ÿã—ãŸé«˜ç—…原性H7N9é³¥ã‚¤ãƒ³ãƒ•ãƒ«ã‚¨ãƒ³ã‚¶ã‚¦ã‚¤ãƒ«ã‚¹ã®æ­£å¸¸è§£æžE 今井正樹. 7th Negative Strand Virus-Japan, æ²–ç¸E 2018/1/15-16, (Oral).
  9. インドãƒã‚·ã‚¢ã«ãŠã‘る高病原性H5N1鳥インフルエンザウイルスã®è§£æžE 今æ‘剛朗, 山田晋弥, 河岡義è£E 7th Negative Strand Virus-Japan, æ²–ç¸E 2018/1/15-16, (Poster).
  10. Characterization of a highly pathogenic avian H7N9 influenza virus. Imai M. 20th International Conference on Emerging Infectious Diseases in the Pacific Rim, æ·±圳EŒä¸­å›½, 2018/1/10, (Oral).

2017

  1. H7N9亜型ã®ã‚¤ãƒ³ãƒ•ルエンザウイルスã®ãƒ’トåˆE›¢æ ªãŒãEãƒªãƒ¡ãƒ©ãƒ¼ã‚¼è›‹ç™½è³ªã«æŒã¤å“ºä¹³é¡žé©å¿œã‚¢ãƒŸãƒŽé…¸å¤‰ç•°ã®è§£æžE å±±å‰èª ä¹E 安原敦æ´E 大石康平, 木曽真紀, 河岡義è£E 第160å›E日本ç£åŒ»å­¦ä¼šå­¦è¡“集ä¼E 鹿å…島大学, 鹿å…å³¶EE017/9/13-15, (Oral).
  2. Novel protective human monoclonal anti-HA stem antibodies against influenza A virus infection. Yamayoshi S, Ito M, Uraki R, Kiso M, Sasaki T, Ikuta K, Kawaoka Y. 17th International Congress of Virology, シンガãƒãEル, 2017/7/17-21, (Poster).
  3. A broadly reactive anti-HA stem monoclonal antibody that inhibits influenza A virus particle release. Yamayoshi S. CAS-IMSUT Workshop on Infectious Diseases, 北京, 中国, 2017/4/13, (Oral).
  4. Development of a novel influenza rapid diagnostic kit specific for the H7 subtype. Iwatsuki-Horimoto K, Shi J, Wang X, Sakai-Tagawa Y, Ito M, Murakami K, Lopes TJS, Nakaishi K, Yamayoshi S, Watabe S, Chen H, Kawaoka Y. The 6th Chinaâ€Japan Bilateral Symposium on All Influenza virus, 北京, 中国, 2017/3/14-15, (Oral).
  5. A broadly reactive human anti-hemagglutinin stem monoclonal antibody that inhibits influenza A virus particle release. Yamayoshi S, Uraki R, Ito M, Kiso M, Nakatsu S, Yasuhara A, Oishi K, Sasaki T, Ikuta K, Kawaoka Y. The 6th Chinaâ€Japan Bilateral Symposium on All Influenza virus, 北京, 中国, 2017/3/14-15, (Oral).

2016

  1. S. Yamayoshi, R. Uraki, M. Ito, M. Kiso, S. Nakatsu, K. Oishi, A. Yasuhara, T. Sasaki, K. Ikuta, Y. Kawaoka , A broadly reactive human anti-HA monoclonal antibody that inhibits influenza A virus particle release, Options IX for the Control of Influenza, Chicago, USA , 2016/8/24-28, (poster).
  2. A. Yasuhara, S. Yamayoshi, M. Ito, R. Uraki, S. Nakatsu, K. Oishi, P. Soni, T. Takenaga, T. Sasaki, K. Ikuta, S. Yamada, Y. Kawaoka, Characterization of the antigenic properties of influenza A(H1N1)pdm09 virus, Options IX for the Control of Influenza, Chicago, USA, 2016/8/24-28, (poster).

2015

  1. æ‘æœ¬è£•ç´€å­ã€E«˜ç—…原性H5N1鳥インフルエンザウイルス感染ã«ã‚ˆã‚‹é‡ç—‡åŒ–ã«ã¯æ„ŸæŸ“åˆæœŸã®ISGsã®ç™ºè¨€ãŒé–¢ä¸Žã™ã‚‹ã€Fourth Negative Strand Virus-Japanã€Okinawa, Japan, January 2015.
  2. 山地玲奈ã€H5N1高病原性鳥インフルエンザウイルスã®ãƒ’トã¸ã®é©å¿œã«é–¢ä¸Žã™ã‚‹ã‚¢ãƒŸãƒŽé…¸ã®åŒå®šã€Fourth Negative Strand Virus-Japanã€Okinawa, Japan, January 2015.

2014

  1. 山地玲奈ã€å±±ç”°æ™‹å¼¥ã€Mai Q. Leã€ä¼Šè—¤ç¦ç¾Žã€å‚井(田å·ï¼‰å„ªå­ã€æ²³å²¡ç¾©è£•ã€H5N1高病原性鳥インフルエンザウイルスã®ãƒ’トã¸ã®é©å¿œã«é–¢ä¸Žã™ã‚‹ã‚¢ãƒŸãƒŽé…¸ã®åŒå®šã€ç¬¬62å›žæ—¥æœ¬ã‚¦ã‚¤ãƒ«ã‚¹å­¦ä¼šå­¦è¡“é›†ä¼šã€æ¨ªæµœã€E014å¹´11æœE/li>
  2. æ‘æœ¬è£•ç´€å­ã€Jason E. Shoemakerã€Mai Q. Leã€ä¼Šè—¤é–ã€ç”°æ‘大輔ã€å‚井(田å·ï¼‰å„ªå­ã€ä»Šäº•åšè²´ã€å²¡æœ¬è²´ä¸–å­ã€çŸ³åž£å®ä»ã€å°ç¬ åŽŸä¸€èª ã€åŒ—é‡Žå®æEã€æ²³å²¡ç¾©è£•ã€E«˜ç—…原性H5N1é³¥ã‚¤ãƒ³ãƒ•ãƒ«ã‚¨ãƒ³ã‚¶ã‚¦ã‚¤ãƒ«ã‚¹ã«æ„ŸæŸ“ã—ãŸã‚«ãƒ‹ã‚¯ã‚¤ã‚¶ãƒ«ã®å®¿ä¸»å¿œç­”ã€ç¬¬62å›žæ—¥æœ¬ã‚¦ã‚¤ãƒ«ã‚¹å­¦ä¼šå­¦è¡“é›†ä¼šã€æ¨ªæµœã€E014å¹´11æœE/li>
  3. 渡辺登喜å­ã€ä¸­å›½ã«ãŠã‘る人ã®H7N9亜型鳥インフルエンザウイルス感染ã®ç¾çжã€ç¬¬157回日本ç£åŒ»å­¦ä¼šå­¦è¡“é›†ä¼šã€æœ­å¹Œã€E014å¹´9æœE/li>
  4. æ‘æœ¬è£•ç´€å­ã€Shoemaker Jasonã€Le Thi Q. Maiã€ä¼Šè—¤é–ã€ç”°æ‘大輔ã€å‚井(田å·ï¼‰å„ªå­ã€ä»Šäº•åšè²´ã€å²¡æœ¬è²´ä¸–å­ã€çŸ³åž£å®ä»ã€å°ç¬ åŽŸä¸€èª ã€åŒ—é‡Žå®æEã€æ²³å²¡ç¾©è£•ã€E«˜ç—…原性H5N1é³¥ã‚¤ãƒ³ãƒ•ãƒ«ã‚¨ãƒ³ã‚¶ã‚¦ã‚¤ãƒ«ã‚¹ã«æ„ŸæŸ“ã—ãŸã‚«ãƒ‹ã‚¯ã‚¤ã‚¶ãƒ«ã®å®¿ä¸»å¿œç­”ã€ç¬¬157回日本ç£åŒ»å­¦ä¼šå­¦è¡“é›†ä¼šã€æœ­å¹Œã€E014å¹´9æœE/li>
  5. å±±å‰èª ä¹Ÿã€ç¦å±±è¡ã€å±±ç”°æ™‹å¼¥ã€Dongming Xhaoã€æ‘ä¸Šæ™‹ã€æµ¦æœ¨éšE¤ªã€æ¸¡è¾ºç™»å–œå­ã€åE田有里å­ã€Gabriele Neumannã€æ²³å²¡ç¾©è£•ã€H7N9鳥インフルエンザウイルスã®PB2タンパク質ã®627KãŠã‚ˆã³701Dã¯å“ºä¹³é¡žã«å¯¾ã™ã‚‹é«˜ç—…原性ã«å¯E¸Žã™ã‚‹ã€ç¬¬157回日本ç£åŒ»å­¦ä¼šå­¦è¡“é›†ä¼šã€æœ­å¹Œã€E014å¹´9æœE/li>
  6. 木曽真紀ã€å¤ç”°è¦ä»‹ã€æ²³å²¡ç¾©è£•ã€ãEウスã«ãŠã‘ã‚‹H5N1高病原性鳥インフルエンザウイルスã«å¯¾ã™ã‚‹æŠ—インフルエンザ薬オセルタミビルã¨T-705ã®ä½µç”¨åŠ¹æžœã€ç¬¬157回日本ç£åŒ»å­¦ä¼šå­¦è¡“é›†ä¼šã€æœ­å¹Œã€E014å¹´9æœE/li>
  7. Yamayoshi S, Watanabe M, Uraki R, Goto H, Kawaoka Y., Identification of a novel viral protein expressed from the PB2 segment of influenza A virus, XVIth International Congress of Virology, Montreal, Canada, July 2014.
  8. Yamaji R, Yamada S, Mai Q Le, Ito M, Sakai-Tagawa Y, Kawaoka Y., Identification of PB2 mutations responsible for the efficient replication of H5N1 influenza viruses in human lung epithelial cells, XVIth International Congress of Virology, Montreal, Canada, July 2014.
  9. Kawaoka Y, Characterization of H7N9 influenza A viruses. ASM Bio Defence and Emerging Diseases Research Meeting, Washington, D.C., USA, February 2014.
  10. Muramoto Y, Shoemaker JE, Mai LTQ, Itho Y, Tamura D, Uraki R, Sakai-Tagawa Y, Imai H, Takano R, Kawakami E, Okamoto K, Ishigaki H, Noda T, Fukuyama S, Ogasawara K, Kitano H, Kawaoka Y., Comparison of gene expression dynamics in non-human primates infected with different H5N1 highly pathogenic avian influenza viruses between different disease severities. 第3回感染症若手フォーラムã€E•·å´Žã€E014å¹´2æœE/li>
  11. Yamayoshi S, Yamada S, Fukuyama, S, Murakami S, Zhao D, Uraki R, Tomita Y, Fujimoto N, Goto K, Ishikawa I, Neumann G, Macken C, Kawaoka Y., Virulence-affecting amino acid changes in the PA protein of H7N9 influenza viruses. Asian-African Research Forum on Emerging and Reemerging Infections - 2014, Sendai, Japan, January 2014.
  12. Watanabe T, Pandemic potential of H7N9 influenza A viruses isolated from humans. Asian-African Research Forum on Emerging and Reemerging Infections - 2014, Sendai, Japan, January 2014.
  13. Muramoto Y, Integrated clinical, pathologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. Asian-African Research Forum on Emerging and Reemerging Infections - 2014, Sendai, Japan, January 2014.
  14. Muramoto Y, Shoemaker JE, Mai LTQ, Itho Y, Tamura D, Uraki R, Sakai-Tagawa Y, Imai H, Takano R, Kawakami E, Okamoto K, Ishigaki H, Noda T, Fukuyama S, Ogasawara K, Kitano H, Kawaoka Y., Comparison of gene expression dynamics in non-human primates infected with different H5N1 highly pathogenic avian influenza viruses between different disease severities. Asian-African Research Forum on Emerging and Reemerging Infections - 2014, Sendai, Japan, January 2014.
  15. å±±å‰èª ä¹Ÿã€A型インフルエンザウイルスã®PB2åˆE¯€ã‹ã‚‰ç™ºç¾ã•れる新è¦ã‚¦ã‚¤ãƒ«ã‚¹è›‹ç™½è³ªã®åŒå®šã€Erd Negative strand Virus-Japan Symposium, Okinawa, Japanã€E014å¹´1æœE/li>
  16. 渡辺登喜å­ã€H7N9インフルエンザウイルスã«ã¤ãE¦ã€ç¬¬E‘回ãƒã‚¤ã‚ªã‚»ã‚­ãƒ¥ãƒªãƒE‚£ãƒ¯ãƒ¼ã‚¯ã‚·ãƒ§ãƒEEã€E014å¹´1æœE/li>
  17. é«™ï¨‘ç´—è˜­ã€æ¸¡é‚‰çœŸæ²»ã€æ¸¡é‚‰ç™»å–œå­ã€å·ä¸Šè‹±è‰¯ã€å±±å‰èª ä¹Ÿã€æ²³å²¡ç¾©è£•ã€ã‚¤ãƒ³ãƒ•ルエンザウイルスã®å¢—殖を抑制ã™ã‚‹æ–°è¦å®¿ä¸»å› å­ãE探索ã€Erd Negative strand Virus-Japan Symposium, Okinawa, Japan, January 2014.
  18. 剿‘å¿ ã€ç¦å±±è¡ã€æ²³å²¡ç¾©è£•ã€ã‚¤ãƒ³ãƒ•ルエンザウイルス感染マウスã®èƒšç”±æ¥ã‚¨ã‚¯ã‚½ã‚½ãƒ¼ãƒ ã®åŒå®šã€Erd Negative strand Virus-Japan Symposium, Okinawa, Japan, January 2014.
  19. 大石康平ã€å±±å‰èª ä¹Ÿã€æ²³å²¡ç¾©è£•ã€A型インフルエンザウイルスãŒç™ºç¾ã™ã‚‹PA-Xã®è›‹ç™½è³ªç™ºç¾æŠ‘制機èEã®è§£æžã€Erd Negative strand Virus-Japan Symposium, Okinawa, Japan, January 2014.
  20. 桂廣亮ã€ç¦å±±è¡ã€æ²³å²¡ç¾©è£•ã€ã‚¤ãƒ³ãƒ•ルエンザウイルス感染回復期ã«ãŠã‘る気管支上皮å†ç”Ÿæ©Ÿæ§‹ãE探索ã€Erd Negative strand Virus-Japan Symposium, Okinawa, Japan, January 2014.

2013

  1. 河岡義裕ã€ä¸­å›½ã«å‡ºç¾ã—ãŸH7N9ã‚¤ãƒ³ãƒ•ãƒ«ã‚¨ãƒ³ã‚¶ã‚¦ã‚¤ãƒ«ã‚¹ã®æ€§çжã€ç¬¬61回日本ウイルス学会学術集会ã€ç¥žæˆ¸ã€E013å¹´11æœE/li>
  2. å±±å‰èª ä¹Ÿã€æ¸¡è¾ºçœŸé‡Œå­ã€äº”è—¤ç§€ç”·ã€æ²³å²¡ç¾©è£•ã€A型インフルエンザウイルスã®ç¬¬E‘åE節ã‹ã‚‰ç™ºç¾ã•れる新è¦ã‚¦ã‚¤ãƒ«ã‚¹è›‹ç™½è³ªã®åŒå®šã€ç¬¬61回日本ウイルス学会学術集会ã€ç¥žæˆ¸ã€E013å¹´11æœE/li>
  3. 渡辺登喜å­ã€ä»Šäº•åšè²´ã€æ‘上晋ã€ä¸­å³¶å…¸å­ã€åE田有里å­ã€è—¤æœ¬å°šæœªã€äº”藤和æEã€å±±å‰èª ä¹Ÿã€æµ¦æœ¨éšE¤ªã€è¥¿è—¤å²³å½¦ã€åE田裕å­ã€E•·è°·å·ç§€æ¨¹ã€ç”°ä»£çœžäººã€æ²³å²¡ç¾©è£•ã€ä¸­å›½ã§ãƒ’トã‹ã‚‰åˆE›¢ã•れãŸH7N9鳥インフルエンザウイルスã®ãƒ•ェレãƒEƒˆã«ãŠã‘ã‚‹é£›æ²«ä¼æ’­æ€§ã€ç¬¬61回日本ウイルス学会学術集会ã€ç¥žæˆ¸ã€E013å¹´11æœE/li>
  4. å‚井(田å·ï¼‰å„ªå­ã€E«˜å±±è‚²ä»£ã€å½±å±±å‹‰ã€åE田裕å­ã€è¥¿è—¤å²³å½¦ã€ç”°ä»£çœžäººã€æ²³å²¡ç¾©è£•ã€E³¥ã‚¤ãƒ³ãƒ•ルエンザA(H7N9)ウイルスã¯è¿E€Ÿè¨ºæ–­ã‚­ãƒEƒˆã§åˆ¤å®šå¯èƒ½ãE  第61回日本ウイルス学会学術集会ã€ç¥žæˆ¸ã€E013å¹´11æœE/li>
  5. 桑原朋å­ã€E‡Žç”°å²³å¿—ã€ç§¦è£•å­ã€å°¾å±±å¤§æ˜Žã€æ²³å²¡ç¾©è£•ã€ã‚¤ãƒ³ãƒ•ルエンザã®ã‚²ãƒŽãƒ ãƒ‘ッケージング機構M2タンパク質ã¨ç›¸äº’作用ã™ã‚‹å®¿ä¸»å› å­ãEåŒå®šã¨æ©ŸèEè§£æžã€ç¬¬61回日本ウイルス学会学術集会ã€ç¥žæˆ¸ã€E013å¹´11æœE/li>
  6. 渡辺登喜å­ã€ä»Šäº•åšè²´ã€æ‘上晋ã€ä¸­å³¶å…¸å­ã€åE田有里å­ã€è—¤æœ¬å°šæœªã€äº”藤和æEã€å±±å‰èª ä¹Ÿã€æµ¦æœ¨éšE¤ªã€è¥¿è—¤å²³å½¦ã€åE田裕å­ã€E•·è°·å·ç§€æ¨¹ã€ç”°ä»£çœžäººã€æ²³å²¡ç¾©è£•ã€ä¸­å›½ã§ãƒ’トã‹ã‚‰åˆE›¢ã•れãŸH7N9鳥インフルエンザウイルスã®ãƒ•ェレãƒEƒˆã«ãŠã‘ã‚‹é£›æ²«ä¼æ’­æ€§ã€ç¬¬61回日本ウイルス学会学術集会ã€ç¥žæˆ¸ã€E013å¹´11æœE/li>
  7. 伊藤ç¦ç¾Žã€æœ¨æ›½çœŸç´€ã€æµ¦æœ¨éšE¤ªã€å‚井(田å·ï¼‰å„ªå­ã€æ›½ç”°å…¬è¼”ã€ç¬›å¹é”å²ã€ä¼Šè—¤å•“å²ã€å±±å£å‰›å£«ã€ä¼Šè—¤å£½å•“ã€æ²³å²¡ç¾©è£•ã€E010å¹´ã‹ã‚‰2011å¹´ã«è¥¿æ—¥æœ¬ã§é³¥ã‹ã‚‰åˆE›¢ã•れãŸH5N1高病原性鳥インフルエンザウイルスã®ãƒžã‚¦ã‚¹ã«ãŠã‘ã‚‹ç—…åŽŸæ€§ã®æ¯”è¼E€ç¬¬61回日本ウイルス学会学術集会ã€ç¥žæˆ¸ã€E013å¹´11æœE/li>
  8. Noda T, Kawaoka Y, Genome packaging mechanism of influenza A viruses. 9th China-Japan Joint Laboratory Workshop, Beijing, China, November 2013.
  9. Kuwahara T, Noda T, Kozuka-Hata H, Oyama M, Kawaoka Y, Identification and characterization of host factors that interact with influenza virus M2 protein. 9th China-Japan Joint Laboratory Workshop, Beijing, China, November 2013.
  10. Kawaoka Y, vRNA structure and how does the polymerase work. VIIIth Options for the Control of Influenza, Cape Town, South Africa, September 2013.
  11. Kawaoka Y, Perspectives on Influenza Pathogenesis. 7th annual CEIRS (Center of Exellence for Influenza Research and Surveillance) Network Meeting, TN, USA, July 2013.
  12. 渡辺登喜å­ã€ä¸­å›½ã§ãƒ’トã‹ã‚‰åˆE›¢ã•れãŸH7N9鳥インフルエンザã«ã¤ãE¦ã€ç¬¬27回インフルエンザ研究è€Eº¤æµãE会シンãƒã‚¸ã‚¦ãƒ ã€E013å¹´6æœE/li>
  13. Kawaoka Y, The pathogenesis of influena virus infections: the contributions of virus and host factors, 28th International Congress of Chemotherapy and Infection, Yokohama, Japan, June 2013.
  14. Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E, Ozawa M, Kawaoka Y, A PB2-KO influenza virus-based bivalent vaccine protects mice against pandemic H1N1 and highly pathogenic H5N1 virus challenges. 15th International Negative Strand Virus meeting. June 2013.
  15. Kiyoko Iwatsuki-Horimoto, Chairul A. Nidom, Ema Qurnianingsih, Winariani Koesoemoprodjo, Reviany V. Nidom, Titi Setyarini, Rahendra RE Sudarsono, Muhamad Y. Alamudi, Kadek Rahmawati, Burhan Hidayat, Shinya Yamada, Maki Kiso, Yoshihiro Kawaoka, Sero-prevalence of influenza viruses in Indonesia, Asian-African Research Forum on Emerging and Reemerging Infections 2013, January 23-24, 2013.
  16. Shinya Yamada, Chairul A. Nidom, Reviany V. Nidom, Kadek Rahmawati, Muhamad Y. Alamudi, Kholik, Iswahyudi, Rahendra PE Sudarsono, Setyarina Indrasari, Ratnani S Hayati, Kiyoko Iwatsuki-Horimoto, and Yoshihiro Kawaoka, Genetic characterization of H5N1 influenza viruses isolated in Indonesia from 2010-2012, Asian-African Research Forum on Emerging and Reemerging Infections 2013, January 23-24, 2013.
  17. Yoshihiro Kawaoka, What has it achieved and why do we need it? Asian-African Research Forum on Emerging and Reemerging Infections 2013, January 24, 2013.

2012

  1. Shinya Yamada, Mai Q Le, Chairul A Nidom, Mutsumi Ito, Yuko Sakai-Tagawa, Yasuo Suzuki, Yoshihiro Kawaoka, Mutations responsible for the efficient replication of H5N1 influenza viruses in normal human epithelial cells, 31st Annual Meeting of American Society for Virology, July 23, 2012.
  2. Shinya Yamada, Biological and Structural Characterization of a host-adapting amino acid in influenza virus. Workshop of Tropical Infectious Diseases, Surabaya, Indonesia, May 29, 2012.
  3. Kiyoko Iwatsuki-Horimoto, Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan, Workshop of Tropical Infectious Diseases, Surabaya, Indonesia, May 29, 2012.
  4. Yamada S, Nidom CA, Nidom RV, Rahmawati K, Alamudi MY, Kohlik, Indrasari S, Hayati RS, Iwatsuki-Horimoto K, Kawaoka Y. Genetic characterization of chicken H5N1 influenza viruses isolated in Indonesia in 2010. Asian-African research forum on emerging and reemerging infections 2012, Kobe, Jan 2012.
  5. Iwatsuki-Horimoto K, Nidom CA, Qurnianingsih E, Koesoemoprodjo W, Nidom RV, Indrasari S, Rahmawati K, Hidayat B, Woelansari ED, Yamada S, Kiso M, Kawaoka Y. Sero-prevalence of Influenza A virus among schoolchildren in Indonesia. Asian-African research forum on emerging and reemerging infections 2012, Kobe, Jan 2012.

2011

  1. Yamada S, Shinya K, Takada A, Ito T, Suzuki T, Suzuki Y, Le QM, Ebina M, Kasai N, Kida H, Horimoto T, Rivailler P, Chen LM, Donis RO, Kawaoka Y. Adaptation of a duck influenza A virus in quail. The 8th China-Japan Joint Laboratory Workshop: Pathogenesis, Gene Regulation and Signal Transduction, Beijing, Nov 2011.
  2. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le MT, Nagamura-Inoue T, Horimoto T, Yamashita N, Kawaoka Y. Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses. XV International Congress of Virology, Sapporo, Sept 2011.
  3. Iwatsuki-Horimoto K, Horimoto T, Tamura D, Kiso M, Kawakami E, Hatakeyama S, Ebihara Y, Koibuchi T, Fujii T, Takahashi K, Shimojima M, Sakai-Tagawa Y, Ito M, Sakabe S, Iwasa A, Takahashi K, Ishii T, Gorai T, Tsuji K, Iwamoto A, Kawaoka Y. Sero-prevalence of pandemic (H1N1) 2009 influenza A virus among schoolchildren and their parents in Tokyo, Japan. XV International Congress of Virology, Sapporo, Sept 2011.

2010

  1. 今井åšè²´ã€æ–°çŸ¢æ­å­ã€E«˜é‡Žé‡ã€æœ¨æ›½çœŸç´€ã€æ‘本裕紀å­ã€å‚éƒ¨æ²™ç¹”ã€æ‘上晋ã€ä¼Šè—¤ç¦ç¾Žã€å±±ç”°æ™‹å¼¥ã€Mai Quynh Liã€å‚井優å­ã€E«˜æ©‹æEã€å¤§æ£®åº·ä¹‹ã€E‡Žç”°å²³å¿—ã€ä¸‹å³¶æ˜Œå¹¸ã€è§’å·å­¦å£«ã€äº”藤秀男ã€å²©é™E ”å­ã€å €æœ¬æ³°ä»‹ã€æ²³å²¡ç¾©è£•「H5N1インフルエンザウイルス高病原性発æ®ã®ãƒ¡ã‚«ãƒ‹ã‚ºãƒ ã€ç¬¬58回日本ウイルス学会学術集会ã€å¾³å³¶ã€E010å¹´11æœE/li>
  2. å‚部沙織ã€å²©é™E ”å­ã€å €æœ¬æ³°ä»‹ã€E«˜é‡Žé‡ã€çºçºˆå¾‹å­ã€å¥¥é‡Žè‰¯ä¿¡ã€æ²³å²¡ç¾©è£•「亜型間交差中和抗体C179ã®H5N1高病原性鳥インフルエンザãŠã‚ˆã³2009å¹´H1N1パンãƒEƒŸãƒE‚¯ã‚¦ã‚¤ãƒ«ã‚¹ã«å¯¾ã™ã‚‹é˜²å¾¡åŠ¹æžœã€ç¬¬58回日本ウイルス学会学術集会ã€å¾³å³¶ã€E010å¹´11æœE/li>
  3. Imai H, Shinya K, Takano R, Kiso M, Muramoto Y, Sakabe S, Murakami S, Ito M, Yamada S, Le QM, Nidom CA, Sakai-Tagawa Y, Takahashi K, Omori Y, Noda T, Shimojima M, Kakugawa S, Goto H, Iwatsuki-Horimoto K, Horimoto T, Kawaoka Y. The HA and NS genes of human H5N1 influenza A virus contribute to its high virulence in ferrets. Xth Awaji International Forum on Infection and Immunity, Awaji, Sept 2010.

2009

  1. æ‘上晋ã€å €æœ¬æ³°ä»‹ã€æ¡‚廣亮ã€ä¸‹å³¶æ˜Œå¹¸ã€æ²³å²¡ç¾©è£•「Vero細胞ã«ãŠã‘る高増殖性インフルエンザワクãƒãƒ³ã‚·ãƒ¼ãƒ‰ã‚¦ã‚¤ãƒ«ã‚¹é–‹ç™ºã®ãŸã‚ã®åŸºç›¤ç ”ç©¶ã€ç¬¬57å›žæ—¥æœ¬ã‚¦ã‚¤ãƒ«ã‚¹å­¦ä¼šå­¦è¡“é›†ä¼šã€æ±äº¬ã€E009å¹´10æœE/li>

2008

  1. 山田晋弥ã€ä¼Šè—¤ç¦ç¾Žã€å‚井(田å·ï¼‰å„ªå­ã€E«˜é‡Žé‡ã€å €æœ¬æ³°ä»‹ã€Eˆ´æœ¨éšE€Eˆ´æœ¨åº·å¤«ã€æ²³å²¡ç¾©è£•ã€H5N1ã‚¤ãƒ³ãƒ•ãƒ«ã‚¨ãƒ³ã‚¶ã‚¦ã‚¤ãƒ«ã‚¹ã®æ­£å¸¸ãƒ’ト呼å¸å™¨ä¸Šçš®ç´°èƒžã«ãŠã‘る増殖性ã«é–¢ã™ã‚‹å¤‰ç•°ã€ç¬¬56回日本ウイルス学会学術集会ã€E008å¹´10æœE8æ—¥
  2. å‚井(田å·ï¼‰å„ªå­ã€Mai Le Thi Quynhã€ä¼Šè—¤ç¦ç¾Žã€å°æ²¢çœŸã€å±±ç”°æ™‹å¼¥ã€æ²³å²¡ç¾©è£•ã€æ„ŸæŸ“æ‚£è€E½“åEã«ãŠã‘ã‚‹H5N1鳥インフルエンザウイルスã®å¤‰ç•°ã€ç¬¬56回日本ウイルス学会学術集会ã€E008å¹´10æœE8æ—¥
  3. æ‘上晋ã€å²©ä½å½©é¦™ã€å²©é™E¼ˆå €æœ¬E‰ç ”å­ã€ä¼Šè—¤ç¦ç¾Žã€æœ¨æ›½çœŸç´€ã€å–œç”°å®ã€E«˜ç”°ç¤¼äººã€Chairul A. Nidomã€Le Quynh Maiã€å±±ç”°æ™‹å¼¥ã€ä»Šäº•åšè²´ã€å‚井(田å·ï¼‰å„ªå­ã€æ²³å²¡ç¾©è£•ã€å €æœ¬æ³°ä»‹ã€H5N1䏿´»åŒ–インフルエンザワクãƒãƒ³ã®ã‚¯ãƒ¬ãƒ¼ãƒ‰é–“交差防御å…疫能ã®è§£æžã€ç¬¬56回日本ウイルス学会学術集会ã€E008å¹´10æœE8æ—¥
  4. æ¸E°´å¥å¤ªã€Chengjun Liã€æ‘本裕紀å­ã€Hualan Chenã€æ²³å²¡ç¾©è£•ã€H5N1インフルエンザウイルスã®é¶èEã«ãŠã‘ã‚‹dominanceã«ã¯NPãŠã‚ˆã³MåˆE¯€ãŒé–¢ä¸Žã™ã‚‹ã€ç¬¬56回日本ウイルス学会学術集会ã€E008å¹´10æœE8æ—¥
  5. æ‘æœ¬è£•ç´€å­ã€ä¼Šè—¤é–ã€ç”°æ‘大輔ã€å‚井(田å·ï¼‰å„ªå­ã€ä»Šäº•åšè²´ã€å²¡æœ¬è²´ä¸–å­ã€çŸ³åž£å®ä»ã€æ–°çŸ¢æ­å­ã€Mai Le Thi Quynhã€å°ç¬ åŽŸä¸€èª ã€æ²³å²¡ç¾©è£•ã€E«˜ç—…原性H5N1鳥インフルエンザウイルスã®ã‚µãƒ«ã«ãŠã‘ã‚‹ç—…åŽŸæ€§ã®æ¯”è¼E€ç¬¬56回日本ウイルス学会学術集会ã€E008å¹´10æœE8æ—¥
  6. 高野é‡ã€å±±ç”°æ™‹å¼¥ã€Chairul A. Nidomã€æ‘本裕紀å­ã€å‚井(田å·ï¼‰å„ªå­ã€Eˆ´æœ¨åº·å¤«ã€Eˆ´æœ¨éšE€æ²³å²¡ç¾©è£•ã€ã‚¤ãƒ³ãƒ‰ãƒã‚·ã‚¢ã®ãƒ–ã‚¿ã‹ã‚‰åˆE›¢ã•れãŸH5N1ã‚¤ãƒ³ãƒ•ãƒ«ã‚¨ãƒ³ã‚¶ã‚¦ã‚¤ãƒ«ã‚¹ã®æ€§çŠ¶è§£æžã€ç¬¬56回日本ウイルス学会学術集会ã€E008å¹´10æœE8æ—¥
  7. Murakami S, Horimoto T, Muramoto Y, Yamada S, Iwasa A, Iwatsuki-Horimoto K, Shimojima M & Kawaoka Y. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. XIV International Congress of Virology. Istanbul, Aug 2008.
  8. Shimizu K, Li C, Muramoto Y, Yamada S, Chen H & Kawaoka Y. The NP and M segments of H5N1 influenza viruses are responsible for dominance in embryonated eggs. The 8th Awaji International Forum on Infection and Immunity. Awaji, Sept 2008.
  9. Muramoto Y, Itoh Y, Tamura D, Sakai-Tagawa Y, Imai H, Okamoto K, Ishigaki I, Shinya K, Le MQ, Ogasawara K & Kawaoka Y. Comparison of pathogenicity of H5N1 influenza viruses in macaques. The 8th Awaji International Forum on Infection and Immunity. Awaji, Sept 2008.
  10. Takano R, Yamada S, Nidom CA, Sakai-Tagawa Y, Muramoto Y, Suzuki T, Suzuki Y & Kawaoka Y. H5N1 influenza viruses from pigs in Indonesia. The 8th Awaji International Forum on Infection and Immunity. Awaji, Sept 2008.
  11. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, Muramoto Y, Ito M, Kiso M, Horimoto T, Shinya K, Sawada T, Kiso M, Usui T, Murata T, Chen H, Lin Y, Hay A, Haire LF, Stevens DJ, Russell RJ, Gamblin SJ, Skehel JJ & Kawaoka Y. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. The 8th Awaji International Forum on Infection and Immunity. Awaji, Sept 2008.

2007

  1. 岩é™E¼ˆå €æœ¬E‰ç ”å­ã€åE田寧å­ã€åEç”°æ­£äººã€æ‘本裕紀å­ã€Hualan Chenã€æ²³å²¡ç¾©è£•ã€å €æœ¬æ³°ä»‹ã€Aåž‹ã¨B型インフルエンザウイルスã®ãƒãƒªãƒ¡ãƒ©ãƒ¼ã‚¼ã‚µãƒ–ユニット間ã®äº’æ›æ€§ã€ç¬¬30回日本åˆE­ç”Ÿç‰©å­¦ä¼šã€æ¨ªæµœã€E007å¹´12æœE1EE5æ—¥
  2. æ‘æœ¬è£•ç´€å­ã€æ–°çŸ¢æ­å­ã€æ‘上晋ã€è§’å·å­¦å£«ã€å²©é™E¼ˆå €æœ¬E‰ç ”å­ã€äº”藤秀男ã€Hualan Chenã€æ²³å²¡ç¾©è£•ã€ãƒ’ト由æ¥ç´°èƒžã«ãŠã‘ã‚‹H5N1鳥インフルエンザウイルスã®ãƒãƒªãƒ¡ãƒ©ãƒ¼ã‚¼æ´»æ€§ã®è§£æžã€ç¬¬55å›žæ—¥æœ¬ã‚¦ã‚¤ãƒ«ã‚¹å­¦ä¼šå­¦è¡“é›†ä¼šã€æœ­å¹Œã€E007å¹´10æœE1EE3æ—¥
  3. 岩é™E¼ˆå €æœ¬E‰ç ”å­ã€åE田寧å­ã€åEç”°æ­£äººã€æ‘本裕紀å­ã€Hualan Chenã€æ²³å²¡ç¾©è£•ã€å €æœ¬æ³°ä»‹ã€B型インフルエンザウイルスã®ãƒãƒªãƒ¡ãƒ©ãƒ¼ã‚¼ã¯A型ウイルスゲノムã®ãƒ—ロモーターをèªè­˜ã—ãE‚‹ã‹ï¼Ÿç¬¬55å›žæ—¥æœ¬ã‚¦ã‚¤ãƒ«ã‚¹å­¦ä¼šå­¦è¡“é›†ä¼šã€æœ­å¹Œã€E007å¹´10æœE1EE3æ—¥
  4. 新矢æ­å­ã€æ‘本裕紀å­ã€Yuwei Gaoã€Guohua Dengã€Shufang Fanã€Qiyun Zhuã€Hualan Chenã€E‡Žç”°å²³å¿—ã€ç”°æ‘大輔ã€ä¼Šè—¤å•“å²ã€ä¼Šè—¤å£½å•“ã€æ²³å²¡ç¾©è£•ã€ã‚¢ã‚«ã‚²ã‚¶ãƒ«ã‚’用ãEŸä¸­å›½ãƒ’ト由æ¥H5N1鳥インフルエンザウイルスã®ç—EŽŸæ€§è§£æžã€ç¬¬55å›žæ—¥æœ¬ã‚¦ã‚¤ãƒ«ã‚¹å­¦ä¼šå­¦è¡“é›†ä¼šã€æœ­å¹Œã€E007å¹´10æœE1EE3æ—¥
  5. Muramoto Y, Shinya K, Gao Y, Deng G, Fan S, Zhu Q, Noda T, Tamura D, Iwatsuki-Horimoto K, Ito H, Ito T, Chen H & Kawaoka Y. Pathogenesis of an H5N1 influenza virus isolated from a human in China in rhesus macaques. The 7th Awaji International Forum on Infection and Immunity. Awaji, Sept 2007.
  6. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, Muramoto Y, Ito M, Kiso M, Horimoto T, Shinya K, Sawada T, Kiso M, Usui T, Murata T, Lin Y, Hay A, Haire LF, Stevens DJ, Russell RJ, Gamblin SJ, Skehel JJ & Kawaoka Y. Haemaggluinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Options for the Control of Influenza VI. Toronto, June 2007.
EEa href="../">ホãEムEEa href="../aboutus/">拠点ã®ç´¹ä»E/a>EEa href="../ibpcas/">生物物çE ”究所EEa href="../imcas/">微生物研究所EEa href="../hvri/">ãƒãƒ«ãƒ“ンç£åŒ»ç ”究所EEa href="../sitemap.html">サイトãEãƒEEEE/div>